<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">@import url(https://themes.googleusercontent.com/fonts/css?kit=fpjTOVmNbO4Lz34iLyptLfjkgxHgj7kMZxw_eDAShR5xs9JnkeDB7_rP14kUvtRWDW48e_gab-0JapO-wuKrDh06if6osnyAslCuLPPf50A);.lst-kix_oew45lvl8ghv-1>li:before{content:"\0025cb   "}.lst-kix_oew45lvl8ghv-3>li:before{content:"\0025cf   "}.lst-kix_oew45lvl8ghv-0>li:before{content:"\0025cf   "}.lst-kix_oew45lvl8ghv-4>li:before{content:"\0025cb   "}.lst-kix_oew45lvl8ghv-5>li:before{content:"\0025a0   "}ul.lst-kix_oew45lvl8ghv-8{list-style-type:none}ul.lst-kix_oew45lvl8ghv-7{list-style-type:none}ul.lst-kix_oew45lvl8ghv-6{list-style-type:none}ul.lst-kix_oew45lvl8ghv-5{list-style-type:none}.lst-kix_oew45lvl8ghv-6>li:before{content:"\0025cf   "}ul.lst-kix_oew45lvl8ghv-4{list-style-type:none}ul.lst-kix_oew45lvl8ghv-3{list-style-type:none}ul.lst-kix_oew45lvl8ghv-2{list-style-type:none}ul.lst-kix_oew45lvl8ghv-1{list-style-type:none}ul.lst-kix_oew45lvl8ghv-0{list-style-type:none}.lst-kix_oew45lvl8ghv-7>li:before{content:"\0025cb   "}.lst-kix_oew45lvl8ghv-8>li:before{content:"\0025a0   "}.lst-kix_oew45lvl8ghv-2>li:before{content:"\0025a0   "}ol{margin:0;padding:0}table td,table th{padding:0}.c25{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-right-width:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.25;page-break-after:avoid;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0pt;border-bottom-style:solid;orphans:2;widows:2;text-align:justify;padding-right:0pt;height:14pt}.c50{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-bottom-color:#cfd5e4;border-right-width:0pt;padding-left:0pt;padding-bottom:4.2pt;line-height:1.25;page-break-after:avoid;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0.8pt;border-bottom-style:solid;orphans:2;widows:2;text-align:justify;padding-right:0pt}.c53{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-right-width:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.25;page-break-after:avoid;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0pt;border-bottom-style:solid;orphans:2;widows:2;text-align:center;padding-right:0pt}.c32{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-right-width:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.25;page-break-after:avoid;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0pt;border-bottom-style:solid;orphans:2;widows:2;text-align:left;padding-right:0pt}.c68{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-right-width:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.25;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0pt;border-bottom-style:solid;orphans:2;widows:2;text-align:justify;padding-right:0pt}.c51{border-right-style:solid;padding-top:0pt;border-top-width:0pt;border-bottom-color:#cfd5e4;border-right-width:0pt;padding-left:0pt;padding-bottom:4.2pt;line-height:1.25;border-left-width:0pt;border-top-style:solid;border-left-style:solid;border-bottom-width:0.8pt;border-bottom-style:solid;orphans:2;widows:2;text-align:justify;padding-right:0pt}.c54{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:123.8pt;border-top-color:#000000;border-bottom-style:solid}.c46{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:44.2pt;border-top-color:#000000;border-bottom-style:solid}.c37{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:85.5pt;border-top-color:#000000;border-bottom-style:solid}.c3{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:112.9pt;border-top-color:#000000;border-bottom-style:solid}.c59{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:60.8pt;border-top-color:#000000;border-bottom-style:solid}.c24{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:61.5pt;border-top-color:#000000;border-bottom-style:solid}.c56{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:75pt;border-top-color:#000000;border-bottom-style:solid}.c16{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:75.2pt;border-top-color:#000000;border-bottom-style:solid}.c57{padding-top:20pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}.c1{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c28{padding-top:16pt;padding-bottom:4pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c5{color:#2a2a2a;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:9pt;font-family:"Merriweather";font-style:normal}.c26{padding-top:0pt;padding-bottom:0pt;line-height:1.150002;orphans:2;widows:2;text-align:justify;height:11pt}.c52{padding-top:18pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}.c77{padding-top:12pt;padding-bottom:2pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c62{margin-left:19.2pt;padding-top:0pt;text-indent:-19.2pt;padding-bottom:0pt;line-height:2.0;text-align:justify}.c58{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c75{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c11{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c76{padding-top:0pt;padding-bottom:3pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c10{padding-top:14pt;padding-bottom:4pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c39{padding-top:0pt;padding-bottom:12pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c33{padding-top:12pt;padding-bottom:12pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c27{padding-top:0pt;padding-bottom:0pt;line-height:1.150002;orphans:2;widows:2;text-align:justify}.c71{padding-top:14pt;padding-bottom:6pt;line-height:1.15;orphans:2;widows:2;text-align:justify}.c29{font-size:9pt;font-family:"Merriweather";color:#2a2a2a;font-weight:400}.c31{padding-top:0pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c9{padding-top:0pt;padding-bottom:12pt;line-height:1.0;text-align:left}.c7{padding-top:0pt;padding-bottom:0pt;line-height:1.0;text-align:justify}.c8{font-size:11.5pt;font-family:"Merriweather";color:#2a2a2a;font-weight:400}.c22{border-spacing:0;border-collapse:collapse;margin-right:auto}.c19{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;color:#1155cc;text-decoration:underline}.c30{color:#2a2a2a;font-weight:400;font-size:11.5pt;font-family:"Arial"}.c72{color:#000000;font-size:22pt;font-family:"Arial"}.c42{color:#2a2a2a;font-size:19.5pt;font-family:"Arial"}.c55{color:#666666;font-size:12pt;font-family:"Arial"}.c47{font-size:11.5pt;font-family:"Merriweather";color:#ff0000}.c73{color:#2a2a2a;font-size:10pt;font-family:"Arial"}.c48{color:#000000;font-size:20pt;font-family:"Arial"}.c45{font-size:9pt;font-family:"Merriweather";color:#2a2a2a}.c67{color:#000000;font-size:13pt;font-family:"Arial"}.c49{color:#000000;font-size:12.5pt;font-family:"Calibri"}.c63{color:#2a2a2a;font-size:17.5pt;font-family:"Arial"}.c41{color:#000000;font-size:16pt;font-family:"Arial"}.c44{color:#000000;font-size:12pt;font-family:"Calibri"}.c20{font-size:10pt;font-family:"Merriweather";color:#2a2a2a}.c60{color:#434343;font-size:14pt;font-family:"Arial"}.c43{font-size:12pt;font-family:"Roboto";color:#1b1b1b}.c0{border:1px solid black;margin:5px}.c23{text-decoration:none;font-style:normal}.c61{color:#2a2a2a;font-size:19.5pt}.c36{color:#2a2a2a;font-size:11.5pt}.c74{color:#000000;font-size:11pt}.c70{max-width:451.4pt;padding:72pt 72pt 72pt 72pt}.c4{vertical-align:baseline;font-style:italic}.c2{color:inherit;text-decoration:inherit}.c69{height:16pt}.c18{font-style:italic}.c17{background-color:#ffffff}.c21{background-color:#ffff00}.c15{font-weight:700}.c66{page-break-after:avoid}.c34{vertical-align:super}.c40{font-weight:400}.c13{height:40pt}.c12{background-color:#fff2cc}.c64{font-family:"Merriweather"}.c14{height:0pt}.c35{height:11pt}.c6{vertical-align:baseline}.c38{height:25.8pt}.c78{font-family:"Arial"}.c65{height:40.7pt}.title{padding-top:0pt;color:#000000;font-size:26pt;padding-bottom:3pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}.subtitle{padding-top:0pt;color:#666666;font-size:15pt;padding-bottom:16pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}li{color:#000000;font-size:11pt;font-family:"Arial"}p{margin:0;color:#000000;font-size:11pt;font-family:"Arial"}h1{padding-top:20pt;color:#000000;font-size:20pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}h2{padding-top:18pt;color:#000000;font-size:16pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}h3{padding-top:16pt;color:#434343;font-size:14pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h4{padding-top:14pt;color:#666666;font-size:12pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}h5{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:justify}h6{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:justify}</style></head><body class="c17 c70 doc-content"><p class="c66 c76 title" id="h.x3zkimzx2nj"><span class="c23 c40 c6 c72">CD19 exon 2 skipping as a potential correlate of anti-CD19 CAR-T therapy relapse</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c75"><span>S&oslash;ren Helweg Dam</span><span class="c34">1</span><span>, Giorgia Moranzoni</span><span class="c34">1</span><span>, Magnus Haraldson H&oslash;ie</span><span class="c34">2</span><span>, </span><span>Signe Modvig</span><span class="c34">3,4</span><span>, Karin A W Wadt</span><span class="c34">4,5</span><span>, Bodil Als-Nielsen</span><span class="c34">4,6</span><span>, Kjeld Schmiegelow</span><span class="c34">4,6</span><span>, </span><span>Mike Bogetofte Barnkob</span><span class="c34">7</span><span>, Kristoffer Vitting-Seerup</span><span class="c34">2</span><span>, Lars R&oslash;nn Olsen</span><span class="c23 c74 c34 c40 c78">1</span></p><p class="c35 c58"><span class="c23 c40 c64 c6 c74"></span></p><p class="c11"><span class="c34">1</span><span class="c1">LEO foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark</span></p><p class="c11"><span class="c34">2</span><span class="c1">Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark</span></p><p class="c11"><span class="c34">3</span><span class="c1">Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet </span></p><p class="c11"><span class="c34">4</span><span class="c1">Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark</span></p><p class="c11"><span class="c34">5</span><span class="c1">Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet </span></p><p class="c11"><span class="c34">6</span><span>Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet</span></p><p class="c11"><span class="c34">7</span><span class="c1">Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Department of Clinical Immunology, Odense University Hospital, University of Southern Denmark, Odense, Denmark</span></p><p class="c11 c35"><span class="c23 c74 c40 c64 c6"></span></p><p class="c11"><span class="c1">Correspondence: lronn@sund.ku.dk</span></p><p class="c11"><span class="c1">Keywords: CAR T-cell therapy, CD19, relapse, prediction, splicing variant, isoform switching</span></p><p class="c11"><span class="c1">Running head: CD19&Delta;exon2 variant and CAR-T relapse</span></p><h1 class="c57" id="h.kkt7hu5xwb6j"><span class="c48 c23 c40 c6">Abstract</span></h1><p class="c11"><span>Relapse following anti-CD19 chimeric antigen receptor (CAR) T cell therapy remains a concern in the treatment of refractory B-cell malignancies. Although the CD19&Delta;exon2 splice variant has been linked to treatment failure, reliable pre-treatment biomarkers for relapse risk are lacking. Here, we analyzed RNA-sequencing data from a small publicly available cohort of four anti-CD19 CAR-T&ndash;treated B-cell acute lymphoblastic leukemia patients, including one responder, one non-responder, and two who relapsed after initial response. We quantified the percent spliced in (PSI) of CD19 exon 2, as a proxy for CD19&Delta;exon2 abundance before and after treatment. The patient with the lowest pre-treatment exon 2 PSI (i.e., highest estimated abundance of CD19&Delta;exon2) experienced the earliest relapse, whereas the complete responder showed no detectable exon 2 skipping. In silico protein structure modeling indicated reduced structural stability of the FMC63 epitope region in the CD19&Delta;exon2 variant, supporting a potential mechanistic link between exon 2 exclusion and antigen escape. Analysis of larger RNA-sequencing datasets from CAR T treatment na&iuml;ve B-cell malignancies and healthy tissues revealed low-level exon 2 skipping in some individuals across both malignant and normal B cells. These findings suggest that CD19 exon 2 skipping may correlate with CAR-T therapy relapse and its presence in pre-treated individuals highlight its potential for evaluation as an RNA- or qPCR-based biomarker in future studies.</span></p><h1 class="c57" id="h.8p3ww5frm52r"><span class="c23 c40 c6 c48">Introduction</span></h1><p class="c39"><span>Chimeric antigen receptor (CAR) T cell therapy has reshaped treatment options for refractory B-cell malignancies </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?5J6SBo&amp;sa=D&amp;source=editors&amp;ust=1761295508834226&amp;usg=AOvVaw17cshoRwy-9yhKNGzDtQLK">[1&ndash;15]</a></span><span>. These therapies use autologous T cells engineered to express a CAR that targets the B-cell surface protein CD19 </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Zu9GqT&amp;sa=D&amp;source=editors&amp;ust=1761295508834583&amp;usg=AOvVaw1ch6bmYgu_YwXuVx7cPemm">[1,13,14,16]</a></span><span>. CD19 CAR-T products have achieved high complete remission rates in B-cell acute lymphoblastic leukemia (B-ALL; ~70&ndash;90%) </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?VhPewl&amp;sa=D&amp;source=editors&amp;ust=1761295508835011&amp;usg=AOvVaw3-MI2xmlOzEJ3oZiEypgh7">[1&ndash;5,20&ndash;22]</a></span><span>&nbsp;and diffuse large B-cell lymphoma (DLBCL; ~50&ndash;75%) </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?WAwwJH&amp;sa=D&amp;source=editors&amp;ust=1761295508835318&amp;usg=AOvVaw2zLcRl8VA9oOlL8phQPTqD">[13,23&ndash;27]</a></span><span>. Nevertheless, a substantial proportion of patients eventually relapse after CD19 CAR-T therapy (B-ALL: ~40&ndash;50% </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?l3stXJ&amp;sa=D&amp;source=editors&amp;ust=1761295508835723&amp;usg=AOvVaw1UBTrWHWIApfIWc8VcBBuE">[5,10&ndash;14,16&ndash;20]</a></span><span>; DLBCL: &le;66% </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mrX5ZI&amp;sa=D&amp;source=editors&amp;ust=1761295508835915&amp;usg=AOvVaw0M0l4r3KiB9UQIkRGTDa-Q">[7,14,23,25,28&ndash;32]</a></span><span class="c1">).</span></p><p class="c33"><span>The mechanisms underlying relapse are multifactorial and incompletely understood </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?q95fnO&amp;sa=D&amp;source=editors&amp;ust=1761295508836211&amp;usg=AOvVaw0iWHDa229efQsUy07bxjtH">[10]</a></span><span>. While limited CAR T cell persistence can contribute to treatment failure </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?KuZaPK&amp;sa=D&amp;source=editors&amp;ust=1761295508836424&amp;usg=AOvVaw0KWQpVrDH2HoaPCZ1MSJ9G">[33,34]</a></span><span>, several studies have identified loss or alteration of the CD19 antigen as a major cause of resistance </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ZYME0U&amp;sa=D&amp;source=editors&amp;ust=1761295508836691&amp;usg=AOvVaw0rN-N9ir7_40RlTZbu1JTv">[35&ndash;46]</a></span><span>.</span><span>&nbsp;All currently approved CD19 CAR-T therapies employ an FMC63-derived single-chain variable fragment that recognizes an epitope encoded by CD19 exons 3 and 4 </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?8vLxrM&amp;sa=D&amp;source=editors&amp;ust=1761295508837087&amp;usg=AOvVaw1BjB1xLlwyBYY-1XeqtdUI">[16,22,47&ndash;50]</a></span><span>. Alternative splicing events in CD19 can destabilize the structure of this region and impair CAR binding </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?oHjNr9&amp;sa=D&amp;source=editors&amp;ust=1761295508837349&amp;usg=AOvVaw3M_aunmY3z4wxnLf3_GbRQ">[35&ndash;37,40]</a></span><span class="c1">. Among these, the CD19&Delta;exon2 variant has been linked to therapy resistance and relapse following CD19 CAR-T treatment. Despite this established association, patients are not currently stratified before therapy based on CD19 splicing patterns, and no validated pre-treatment biomarkers exist to predict relapse risk.</span></p><p class="c33"><span class="c1">In this study, we investigated whether CD19 exon 2 skipping detectable at the mRNA level could serve as a correlate of CD19 CAR-T therapy outcomes. Specifically, we quantified the percent spliced in (PSI) of CD19 exon 2, calculated from exon 1&ndash;3, exon 1&ndash;2, and exon 2&ndash;3 splice-junction reads, in a small publicly available cohort of B-ALL patients treated with CD19 CAR-T therapy. We further examined the structural implications of exon 2 skipping using in silico protein modeling and assessed its baseline prevalence in B-ALL, DLBCL, and healthy blood and spleen samples. This approach aims to determine whether pre-treatment splicing patterns can inform relapse risk and whether qPCR-based detection of exon 2 skipping could provide a practical biomarker for clinical monitoring.</span></p><p class="c11"><span>CD19-directed CAR T (CART-19) therapies have &nbsp;shown </span><span>promising complete </span><sup><a href="#cmnt1" id="cmnt_ref1">[a]</a></sup><sup><a href="#cmnt2" id="cmnt_ref2">[b]</a></sup><sup><a href="#cmnt3" id="cmnt_ref3">[c]</a></sup><sup><a href="#cmnt4" id="cmnt_ref4">[d]</a></sup><sup><a href="#cmnt5" id="cmnt_ref5">[e]</a></sup><sup><a href="#cmnt6" id="cmnt_ref6">[f]</a></sup><sup><a href="#cmnt7" id="cmnt_ref7">[g]</a></sup></p><h2 class="c17 c50" id="h.c76nyldx2li2"><span class="c61 c15">Materials and methods</span></h2><h3 class="c17 c66 c68" id="h.46cx2s6rzrh9"><span class="c23 c15 c6 c63">Datasets</span></h3><p class="c11"><span class="c8 c17">Table 1 lists the analysed datasets, which are also detailed in the following sections</span><sup><a href="#cmnt8" id="cmnt_ref8">[h]</a></sup><span class="c8 c17">.</span></p><p class="c11 c35"><span class="c23 c17 c6 c30"></span></p><p class="c11"><span class="c20 c17 c15">Table 1.</span><sup><a href="#cmnt9" id="cmnt_ref9">[i]</a></sup><span class="c36">&nbsp;</span><span class="c20 c17 c40">Overview of datasets. The &ldquo;data type&rdquo; column describes whether raw reads were analysed or if the analysis was done using </span><span class="c20 c18 c17 c40">snapcount</span><span class="c20 c17 c40">&nbsp;</span><span class="c20 c17 c40">compilations</span><span class="c20 c17 c40">.</span></p><table class="c22"><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6">Dataset</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6"># Samples</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6">Data type</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6">Median age (range)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6">%male</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c20 c23 c15 c6">&nbsp;Source</span></p></td></tr><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">B-ALL</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">79</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">raw reads</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c29">(</span><span class="c29">1-17</span><span class="c5">)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7 c35"><span class="c5"></span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">iCOPE</span></p></td></tr><tr class="c65"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">DLBCL</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">553</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">snapcount </span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">63 (18-86)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">52.2</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c31"><span class="c29">GOYA </span><span class="c29 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?nSA6A2&amp;sa=D&amp;source=editors&amp;ust=1761295508844675&amp;usg=AOvVaw3g932DZ5ynxy1Hfyw_mXWD">[56,57]</a></span></p></td></tr><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c29">CLL</span><sup><a href="#cmnt10" id="cmnt_ref10">[j]</a></sup></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7 c35"><span class="c5"></span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">snapcount </span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7 c35"><span class="c5"></span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7 c35"><span class="c5"></span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c31 c35"><span class="c5"></span></p></td></tr><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">CART-19-treated B-ALL</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">4</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c29">raw reads</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">52 (29-59)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">50</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c11"><span class="c29">Zhang et al. </span><span class="c29"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?HnnsV2&amp;sa=D&amp;source=editors&amp;ust=1761295508847560&amp;usg=AOvVaw28KnqMU7rHsxy_3CHGXNqw">[12]</a></span></p></td></tr><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">Healthy blood</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">1048</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">snapcount </span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">53 (20-79)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">65.8</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c31"><span class="c29">GTEx database </span><span class="c29 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1oWe1e&amp;sa=D&amp;source=editors&amp;ust=1761295508848893&amp;usg=AOvVaw0AlFfEmf_0S6ob1F8YnxnF">[58]</a></span></p></td></tr><tr class="c14"><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">Healthy spleen</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">255</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">snapcount </span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">52 (20-79)</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c7"><span class="c5">63.9</span></p></td><td class="c16" colspan="1" rowspan="1"><p class="c31"><span class="c29">GTEx database </span><span class="c29 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?Wy3uWP&amp;sa=D&amp;source=editors&amp;ust=1761295508850131&amp;usg=AOvVaw3fd9jORDmRu0eWujo8MtBn">[58]</a></span></p></td></tr></table><h3 class="c17 c25" id="h.81uob0xszuax"><span class="c8 c23 c17 c6"></span></h3><table class="c22"><tr class="c13"><td class="c54" colspan="1" rowspan="1"><h3 class="c53 c17" id="h.81uob0xszuax-1"><span class="c45 c17 c15">Dataset</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c53 c17" id="h.81uob0xszuax-2"><span class="c17 c15 c45">Samples (n)</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c53 c17" id="h.81uob0xszuax-3"><span class="c45 c17 c15">Data type</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c53 c17" id="h.81uob0xszuax-4"><span class="c45 c17 c15">Median age (range)</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c53 c17" id="h.81uob0xszuax-5"><span class="c45 c17 c15">% Male</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c17 c53" id="h.81uob0xszuax-6"><span class="c45 c17 c15">Source</span></h3></td></tr><tr class="c38"><td class="c54" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-7"><span class="c5 c17">B-ALL</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-8"><span class="c5 c17">79</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-9"><span class="c5 c17">Raw reads</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-10"><span class="c5 c17">1&ndash;17</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-11"><span class="c5 c17">&mdash;</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-12"><span class="c5 c17">iCOPE</span></h3></td></tr><tr class="c13"><td class="c54" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-13"><span class="c5 c17">DLBCL</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-14"><span class="c5 c17">553</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-15"><span class="c5 c17">Snapcount</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-16"><span class="c5 c17">63 (18&ndash;86)</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-17"><span class="c5 c17">52.2 %</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-18"><span class="c5 c17">GOYA [56, 57]</span></h3></td></tr><tr class="c13"><td class="c54" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-19"><span class="c5 c17">CD19 CAR-T&ndash;treated B-ALL</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-20"><span class="c5 c17">4</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-21"><span class="c5 c17">Raw reads</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-22"><span class="c5 c17">52 (29&ndash;59)</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-23"><span class="c5 c17">50 %</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-24"><span class="c5 c17">Zhang et al. [12]</span></h3></td></tr><tr class="c38"><td class="c54" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-25"><span class="c5 c17">Healthy blood</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-26"><span class="c5 c17">1,048</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-27"><span class="c5 c17">Snapcount</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-28"><span class="c5 c17">53 (20&ndash;79)</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-29"><span class="c5 c17">65.8 %</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-30"><span class="c5 c17">GTEx v2 [58]</span></h3></td></tr><tr class="c38"><td class="c54" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-31"><span class="c5 c17">Healthy spleen</span></h3></td><td class="c24" colspan="1" rowspan="1"><h3 class="c17 c32" id="h.81uob0xszuax-32"><span class="c5 c17">255</span></h3></td><td class="c59" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-33"><span class="c5 c17">Snapcount</span></h3></td><td class="c37" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-34"><span class="c5 c17">52 (20&ndash;79)</span></h3></td><td class="c46" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.81uob0xszuax-35"><span class="c5 c17">63.9 %</span></h3></td><td class="c56" colspan="1" rowspan="1"><h3 class="c32 c17" id="h.17ilsm9iuqui"><span class="c5 c17">GTEx v2 [58]</span></h3></td></tr></table><h3 class="c25 c17" id="h.81uob0xszuax-36"><span class="c8 c23 c17 c6"></span></h3><h4 class="c10 c66" id="h.y1sv6f3zllpv"><span>B-ALL</span><span>&nbsp;cohort </span><sup><a href="#cmnt11" id="cmnt_ref11">[k]</a></sup></h4><p class="c11"><span class="c8 c17">We included 79 Danish pediatric patients (age 1-17 years) with B-cell precursor ALL for the study. Patients were treated according to the NOPHO </span><span class="c8 c17">ALL2008</span><span class="c8 c17">&nbsp;</span><span class="c17 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ajLOI1&amp;sa=D&amp;source=editors&amp;ust=1761295508858245&amp;usg=AOvVaw2H54hlajz-OZXeSr6YQ5pm">[59]</a></span><span class="c8 c17">&nbsp;</span><span class="c8 c17">/ ALLTogether (clinicaltrials.gov ID NCT03911128</span><span class="c17 c40 c43">)</span><span class="c8 c17">&nbsp;protocol</span><span class="c8 c17">s</span><sup><a href="#cmnt12" id="cmnt_ref12">[l]</a></sup><sup><a href="#cmnt13" id="cmnt_ref13">[m]</a></sup><sup><a href="#cmnt14" id="cmnt_ref14">[n]</a></sup><span class="c8 c17">. Bone marrow was sampled at time of diagnosis, prior to initiation of therapy, and RNA sequencing was performed on this </span><span class="c8 c17">material</span><sup><a href="#cmnt15" id="cmnt_ref15">[o]</a></sup><span class="c8 c17">&nbsp;as part of another study (iCOPE/STAGING, Capital Region Ethics Committee </span><span class="c17 c40 c47">ID: </span><span class="c8 c17">). </span><span class="c8 c17">We trimmed the RNA-seq reads from the patients using </span><span class="c8 c18 c17">fastp</span><span class="c8 c17">&nbsp;(v.0.23.4) </span><span class="c17 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?wRA8Ik&amp;sa=D&amp;source=editors&amp;ust=1761295508859378&amp;usg=AOvVaw3aFqQ4YOqYz6_DuvBu0f8s">[60]</a></span><span class="c8 c17">&nbsp;and mapped </span><span class="c8 c17">to the human genome (GRCh38, release 107)</span><span class="c8 c17">&nbsp;using </span><span class="c8 c18 c17">STAR</span><span class="c8 c17">&nbsp;(v.2.7.11b) </span><span class="c17 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?FuRli0&amp;sa=D&amp;source=editors&amp;ust=1761295508859749&amp;usg=AOvVaw1_bFoXEfruutGqJQEI1JPa">[61]</a></span><span class="c8 c17">.</span></p><h4 class="c10 c66" id="h.o5io8nfp2caf"><span class="c55 c23 c40 c6">DLBCL cohort </span></h4><p class="c11"><span class="c8">We extracted 553 pre-treatment samples from DLBCL patients from </span><span class="c8 c17">the GOYA study </span><span class="c8 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?jF7KIT&amp;sa=D&amp;source=editors&amp;ust=1761295508860335&amp;usg=AOvVaw3mZTilnh3T4EG0DxxpsFuw">[56,57]</a></span><span class="c8">, </span><span class="c8 c17">available in</span><span class="c8 c17">&nbsp;the SRA database </span><span class="c8 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?ynrv6J&amp;sa=D&amp;source=editors&amp;ust=1761295508860632&amp;usg=AOvVaw3JrmCMeiuGc1fzFgU5AiH_">[62]</a></span><span class="c8 c17">&nbsp;(SRP183071), using </span><span class="c8 c18 c17">snapcount</span><span class="c8 c17">&nbsp;(v.1.14.0) </span><span class="c8 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?P94QD5&amp;sa=D&amp;source=editors&amp;ust=1761295508860939&amp;usg=AOvVaw3krBHj0XmVelfYfZM3gEvn">[63]</a></span><span class="c8 c17">. The cells were classified as activated B-cells (n=151), germinal center B-cells (n=298), or unclassified (n=104), as described by McCord et al. </span><span class="c6 c8"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?rBpYP4&amp;sa=D&amp;source=editors&amp;ust=1761295508861309&amp;usg=AOvVaw2vQN2OT4gH9CNMkiy2pSNP">[57]</a></span><span class="c8 c17">.</span></p><h4 class="c10 c66" id="h.23ulgfqwmpq6"><span class="c55 c23 c40 c6">Healthy cohort</span></h4><p class="c11"><span class="c8 c17">We extracted healthy blood and spleen samples from the GTEx </span><span class="c8 c17 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?6L9rVN&amp;sa=D&amp;source=editors&amp;ust=1761295508861797&amp;usg=AOvVaw0BZcPizQz0SVTzIXRvLrhI">[58]</a></span><span class="c8 c17">&nbsp;</span><span class="c8 c17">version 2 compilation</span><span class="c8 c17">&nbsp;using </span><span class="c8 c17 c18">snapcount</span><span class="c8 c17">&nbsp;(v.1.14.0</span><span class="c8 c17">).</span></p><h4 class="c10 c66" id="h.eazrl7lmh93d"><span>CART-19-treated </span><span>B-ALL</span><span>&nbsp;patient cohort analysis</span></h4><p class="c11"><span>To correlate the CD19&#120491;exon2 splice variant with relapse risk, we extracted the raw RNA-seq data from a CART-19 therapy study conducted by Zhang et al. </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?oYYGTl&amp;sa=D&amp;source=editors&amp;ust=1761295508862730&amp;usg=AOvVaw1uMeVuorKZc-cHW1L5oxe8">[12]</a></span><span>. This study encompassed four patients with diverse tumor burdens, each demonstrating varied responses to the therapy. Bone marrow samples were procured pre-treatment and 14 days post-treatment (</span><span class="c15">Table 2</span><span class="c1">).</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c11"><span>The raw reads were trimmed with fastp (v.&#8203;&#8203;0.21.1) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?AxMb1h&amp;sa=D&amp;source=editors&amp;ust=1761295508863353&amp;usg=AOvVaw0LA6oCBn2CAVRH27_dqpJd">[60]</a></span><span>&nbsp;and mapped to the human genome (GRCh38, release 107) using STAR (v.2.7.10a) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?C2lI9R&amp;sa=D&amp;source=editors&amp;ust=1761295508863601&amp;usg=AOvVaw3sttRQUZKYL8aSgZGYwHwe">[61]</a></span><span>. The splice variants of exon 1-4 of CD19 were computed and visualized using ggsashimi (v.1.1.5) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?NV5ej9&amp;sa=D&amp;source=editors&amp;ust=1761295508863898&amp;usg=AOvVaw1ievLPbFCALON7hLwfX40W">[64]</a></span><span class="c1">.</span></p><p class="c11 c35"><span class="c8 c23 c6"></span></p><p class="c11"><span class="c15">Table 2</span><span>.</span><span>&nbsp;Overview of B-ALL patients from Zhang et al. </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?TX1J1L&amp;sa=D&amp;source=editors&amp;ust=1761295508864362&amp;usg=AOvVaw0B7gNp9yI2dSsZOHyZZ5Ee">[12]</a></span><span class="c1">. TB: Tumor burden as percentage of malignant cells among all B cells.</span></p><table class="c22"><tr class="c14"><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c23 c36 c15 c64 c6">Patient</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c23 c36 c15 c6 c64">Responder</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c23 c36 c15 c64 c6">Relapse</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c23 c36 c15 c64 c6">&nbsp;TB (%) Day 0</span></p></td></tr><tr class="c14"><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">A</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">Yes</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">1.5 months</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">17.92</span></p></td></tr><tr class="c14"><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">B</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">No</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">N/A</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">65.46</span></p></td></tr><tr class="c14"><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">C</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">Yes</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">13 months</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">0.25</span></p></td></tr><tr class="c14"><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">D</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">Yes</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">N/A</span></p></td><td class="c3" colspan="1" rowspan="1"><p class="c7"><span class="c8 c23 c6">0.5</span></p></td></tr></table><p class="c11 c35"><span class="c1"></span></p><h3 class="c28" id="h.qbj3ah6lt5ae"><span>The CD19&#120491;exon2 </span><span>topology</span><span class="c23 c40 c6 c60">&nbsp;and structure</span></h3><p class="c11"><span>We acquired the canonical and isoform sequences from UniProt (Accession: P15391). The protein sequences were aligned with the R package msa (v.1.36) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?nUa7lG&amp;sa=D&amp;source=editors&amp;ust=1761295508870520&amp;usg=AOvVaw332Q18Z7v81KurYWZlEEFg">[65]</a></span><span>&nbsp;and predicted the topology of each isoform using DeepTMHMM (v.1.0) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?0npevD&amp;sa=D&amp;source=editors&amp;ust=1761295508870936&amp;usg=AOvVaw0xtJrm2V6wieMSVfQE2lwq">[66]</a></span><span class="c1">.</span></p><p class="c11"><span>We predicted the protein structures using AlphaFold 3 </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mMk2Nk&amp;sa=D&amp;source=editors&amp;ust=1761295508871366&amp;usg=AOvVaw35zxlhRtrCUtsb8TeZXqXn">[52]</a></span><span>&nbsp;and rendered the structure images with PyMol (v.3.1) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?seAzmA&amp;sa=D&amp;source=editors&amp;ust=1761295508871728&amp;usg=AOvVaw3apoGDGKFnrcVkc7hRq_9r">[67]</a></span><span>. A second opinion prediction was made using ESM-IF1 inverse folding </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?HJc1zO&amp;sa=D&amp;source=editors&amp;ust=1761295508872197&amp;usg=AOvVaw3RJSs-vOam8d845R1j_8eF">[68]</a></span><span>, and a pseudo-perplexity </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tdckI7&amp;sa=D&amp;source=editors&amp;ust=1761295508872478&amp;usg=AOvVaw0FN4_3Vn473aYEG5t-17xt">[53]</a></span><span class="c1">&nbsp;was computed as the exponentiated average PDB residue log-probability.</span></p><h3 class="c28" id="h.lt5vj951peg9"><span>CD19&#120491;exon2 percent spliced in</span></h3><p class="c11"><span>For the B-ALL cohort</span><span>, outrigger (v.1.1.1) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?latoEu&amp;sa=D&amp;source=editors&amp;ust=1761295508873394&amp;usg=AOvVaw2nww1RYnDfpsnGmxyxQIsC">[69]</a></span><span>&nbsp;computed the percent spliced in of CD19&#120491;exon2. For samples from snapcount compilations, we computed the percent spliced in of CD19&#120491;exon2 using snapcount (v.1.14.0) </span><span class="c19 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?i83KDo&amp;sa=D&amp;source=editors&amp;ust=1761295508874063&amp;usg=AOvVaw0ClziNN8AHmK_iEwfL9NCB">[63]</a></span><span>.</span></p><h3 class="c10" id="h.m28avwdrfmwh"><span class="c23 c15 c6 c67">RNA Sequencing and Splicing Quantification</span></h3><p class="c33"><span>For the B-ALL cohort, bone marrow samples were collected at diagnosis before therapy initiation. RNA was extracted and sequenced as part of the iCOPE/STAGING study (Capital Region Ethics Committee ID [redacted]).<br> Reads were trimmed using </span><span class="c15">fastp</span><span>&nbsp;(v0.23.4) [60] and aligned to the human genome (</span><span class="c15">GRCh38</span><span>, release 107) with </span><span class="c15">STAR</span><span class="c1">&nbsp;(v2.7.11b) [61].</span></p><p class="c33"><span>Splice junction reads corresponding to CD19 exons 1&ndash;2, 1&ndash;3, and 2&ndash;3 were extracted from aligned BAM files. The </span><span class="c15">percent spliced-in (PSI)</span><span class="c1">&nbsp;value for exon 2 was calculated as:</span></p><p class="c11"><span class="c1">PSIexon 2=reads1&ndash;2+reads2&ndash;3reads1&ndash;2+reads1&ndash;3+reads2&ndash;3\text{PSI}_{\text{exon 2}} = \frac{\text{reads}_{1&ndash;2} + \text{reads}_{2&ndash;3}}{\text{reads}_{1&ndash;2} + \text{reads}_{1&ndash;3} + \text{reads}_{2&ndash;3}}PSIexon 2&#8203;=reads1&ndash;2&#8203;+reads1&ndash;3&#8203;+reads2&ndash;3&#8203;reads1&ndash;2&#8203;+reads2&ndash;3&#8203;&#8203;</span></p><p class="c33"><span>where a lower PSI reflects increased exon 2 skipping. Junction counts were visualized as </span><span class="c15">sashimi plots</span><span class="c1">&nbsp;to display read coverage across exons 1&ndash;4.</span></p><p class="c33"><span>For DLBCL, CLL, and healthy samples, splice junction counts were obtained from </span><span class="c15">snapcount</span><span class="c1">&nbsp;(v1.14.0) [63], which compiles exon&ndash;exon junction quantifications from large public RNA-seq collections (GOYA, GTEx). PSI values were computed using the same formula to ensure consistency across datasets.</span></p><h2 class="c71" id="h.n94z0fuhw0p7"><span class="c41 c23 c40 c6">Structural Modeling</span></h2><p class="c33"><span class="c1">Protein structures of full-length CD19 and the &Delta;exon2 variant were predicted using AlphaFold 3. Predictions were based on the UniProt sequence P15391. The FMC63 single-chain variable fragment (scFv) was modeled from known complex templates (e.g., PDB 6AL5) and docked to each CD19 model using standard alignment procedures.</span></p><p class="c33"><span class="c1">Per-residue model confidence was assessed using pLDDT scores provided by AlphaFold. These scores serve as estimates of local model confidence rather than direct measures of biophysical stability. Models were visualized and compared using PyMOL (v2.5) with domains colored by topology or pLDDT values.</span></p><h2 class="c71" id="h.ol1eyvo4x9l"><span class="c41 c23 c40 c6">Visualization and Statistical Analysis</span></h2><p class="c11"><span class="c1">All computational analyses and figure generation were performed in R (v4.3.1) and Python (v3.10). Sashimi plots were generated using ggsashimi, and histograms of PSI distributions were plotted with ggplot2. No formal hypothesis testing was applied due to limited sample size in the CAR-T&ndash;treated cohort; all findings were interpreted descriptively.</span></p><p class="c33 c35"><span class="c1"></span></p><p class="c11 c35"><span class="c1"></span></p><h1 class="c57" id="h.qpzr2rkevcwj"><span>Results</span></h1><h2 class="c77" id="h.12i0tvdhwjuw"><span class="c41 c23 c40 c6">CD19 &Delta;exon2 exhibits reduced structural stability in the FMC63 epitope region compared with canonical CD19</span></h2><p class="c33"><span>To assess the structural consequences of exon 2 skipping, we first compared the domain topology of canonical CD19 and the predicted &Delta;exon2 variant (Fig. 1A). The alignment shows that removal of exon 2 shortens the extracellular portion of CD19 while leaving the FMC63-recognized epitope, encoded by exons 3&ndash;4, intact. Structural modeling using AlphaFold 3 reproduced the published CD19&ndash;FMC63 complex </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?atiHFE&amp;sa=D&amp;source=editors&amp;ust=1761295508881601&amp;usg=AOvVaw12UfFElceJvWn0Z3flRDah">[52]</a></span><sup><a href="#cmnt16" id="cmnt_ref16">[p]</a></sup><span>&nbsp;(Fig. 1B) and predicted an altered fold for the &Delta;exon2 variant (Fig. 1C). Coloring the models by domain boundaries illustrated a subtle displacement of the ectodomain relative to the transmembrane region, suggesting reduced overall stability. When colored by per-residue pLDDT scores, the &Delta;exon2 model showed markedly decreased confidence within the epitope region compared with the canonical structure (Fig. 1D&ndash;E). pLDDT is known to correlate with stability </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?k3ftxU&amp;sa=D&amp;source=editors&amp;ust=1761295508882550&amp;usg=AOvVaw3B5YsfMKcmJ90F39jqPyqW">[51]</a></span><span class="c1">, and is consistent with local destabilization rather than epitope loss. Having established that exon 2 skipping likely negatively affects the structural integrity of the FMC63 binding region, we next examined whether this event could be detected in pre-treatment RNA samples from CD19 CAR-T&ndash;treated patients.</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c11"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 602.00px; height: 569.97px;"><img alt="" src="images/image4.png" style="width: 602.00px; height: 623.00px; margin-left: 0.00px; margin-top: -23.03px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c11"><span class="c15">Figure 1</span><span>. A) Aligned membrane topology of canonical CD19 and CD19&#120491;exon2 with annotation of the FMC63 epitope (orange). B) Predicted 3D structure of canonical CD19:Antibody and C) predicted 3D structure of CD19&#120491;exon2:Antibody. The colors annotate the FMC63 epitope (orange), exon 2 (green), and the FMC63 antibody (grey).</span></p><p class="c11 c35"><span class="c1"></span></p><h2 class="c71" id="h.plt57kgk3oab"><span class="c41 c23 c40 c6">CD19 exon 2 skipping correlates with relapse in a small cohort of CD19 CAR-T treated patients</span></h2><p class="c33"><span>To explore whether exon 2 skipping occurs in CD19 CAR-T treated patients and whether it may quantitatively relate to treatment outcome, we analyzed RNA-sequencing data from a small publicly available cohort of four B-ALL patients representing one complete responder, one non-responder, and two who relapsed after initial remission (</span><span class="c15">Table 2</span><span>) </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?GHYO1H&amp;sa=D&amp;source=editors&amp;ust=1761295508884906&amp;usg=AOvVaw18gvRgza9eAkx78UByGV0t">[</a></span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?GHYO1H&amp;sa=D&amp;source=editors&amp;ust=1761295508885038&amp;usg=AOvVaw0hv5X_r0o6degFF4yf0zkF">12</a></span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?GHYO1H&amp;sa=D&amp;source=editors&amp;ust=1761295508885121&amp;usg=AOvVaw1ESHPXNM_-tHG_wawO8kKG">]</a></span><span>. For each sample, we quantified exon 1&ndash;3 junction reads as a proxy for exon 2 skipping. Sashimi plots of the CD19 exon 1&ndash;4 region revealed pronounced exon 1&ndash;3 junction coverage in the non-responder before therapy, consistent with extensive exon 2 skipping, whereas the complete responder showed no detectable exon 1&ndash;3 junction reads (</span><span class="c15">Figure 2A</span><span>). Post-treatment samples displayed generally sparse coverage for CD19, reflecting the expected B-cell depletion after CAR-T therapy; however, patient A (rapid relapse) and B (no response) retained higher levels of CD19 expression and increased exon 1&ndash;3 junction usage relative to patient C (slow relapse) and D (no relapse) (</span><span class="c15">Figure 2B</span><span class="c1">). Patient A exhibited the lowest pre-treatment exon 2 PSI, while patient D showed none. Although this small cohort precludes statistical inference, the consistent pattern across individuals suggests that reduced inclusion of exon 2 may be associated with CD19 CAR-T therapy failure. To place these observations in context, we next examined the baseline prevalence of exon 2 skipping in untreated malignant and normal B-cell populations.</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c26"><span class="c23 c15 c6 c44"></span></p><p class="c27"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 601.70px; height: 340.00px;"><img alt="" src="images/image5.png" style="width: 601.70px; height: 340.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><sup><a href="#cmnt17" id="cmnt_ref17">[q]</a></sup><sup><a href="#cmnt18" id="cmnt_ref18">[r]</a></sup><sup><a href="#cmnt19" id="cmnt_ref19">[s]</a></sup><sup><a href="#cmnt20" id="cmnt_ref20">[t]</a></sup><sup><a href="#cmnt21" id="cmnt_ref21">[u]</a></sup></p><p class="c11"><span class="c20 c15">Figure 2</span><span class="c20 c15">.</span><span class="c8">&nbsp;</span><span class="c20 c40">Sashimi plot of the CD19 splice junctions of the four patients. Purple circles highlight the CD19&#120491;exon2 splice junction in each patient.</span></p><p class="c11 c35"><span class="c8 c6 c23"></span></p><h2 class="c71 c66" id="h.hb0wi54yzn1o"><span>CD19&#120491;exon2 is detectable at low levels in treatment-na&iuml;ve B-cell malignancies and normal B-cell rich tissues</span></h2><p class="c33"><span>To evaluate the prevalence of pre-treatment CD19&#120491;exon2 in a broader context, we examined B-cell&ndash;rich tissues and malignancies using independent RNA-seq datasets (</span><span class="c15">Figure 3A&ndash;D</span><span>). Here, we quantified the percent spliced in (PSI) of </span><span>CD19</span><span>&nbsp;exon 2 &ndash; a metric that normalizes the exon 1-3 junction reads to exon 1-2 and exon 2-3 junction read depth. As such, a PSI of 100% is a proxy for no detected </span><span>CD19</span><span>&#120491;exon2. In the B-ALL cohort, </span><span class="c21">DESCRIPTION OF WHAT WE SEE LARS NEEDS PERCENT</span><span>. This distribution closely resembled healthy blood and spleen, where </span><span class="c21">DESCRIPTION OF WHAT WE SEE LARS NEEDS PERCENT</span><span>. In contrast, DLBCL displayed greater heterogeneity: </span><span class="c21">DESCRIPTION OF WHAT WE SEE LARS NEEDS PERCENT</span><span class="c1">. Within each cohort, we tested whether any sample-level covariates (age, sex, prior therapy, and cytogenetics) correlate with exon 2 PSI, but found no significant correlation. The presence of measurable CD19 &Delta;exon2 transcripts across treatment-na&iuml;ve malignant and healthy B-cell samples demonstrates that this splicing event occurs at low but detectable levels under physiological conditions. This finding indicates that exon 2 PSI can be robustly quantified from standard RNA-seq data, providing the technical basis for evaluating CD19 &Delta;exon2 as a potential pre-treatment biomarker of CAR-T therapy response. Moreover, the detection of CD19 &Delta;exon2 in untreated samples supports a model in which this isoform represents a naturally occurring, low-frequency splice variant rather than a therapy-induced transcript. Under the selective pressure of CD19-directed CAR-T therapy, malignant cells expressing this pre-existing variant may gain a survival advantage, resulting in apparent enrichment of the isoform in relapsed disease.</span></p><h3 class="c28" id="h.shpvzhhig829"><span class="c12">CD19&#120491;exon2</span><span class="c60 c23 c40 c12 c6">&nbsp;is detectable in both B cell malignancy patients and healthy donors</span></h3><p class="c11"><span class="c12">Next, w</span><span class="c12">e compared the prevalence of the splice variant in B-ALL and DLBCL patients</span><span class="c12">&nbsp;to blood and spleen samples</span><span class="c12">&nbsp;from healthy donors. We quantified the percent spliced in (PSI) of </span><span class="c12">CD19</span><span class="c12">&nbsp;exon 2 &ndash; a metric that normalizes the exon 1-3 junction reads to exon 1-2 and exon 2-3 junction read depth. As such, a PSI of 100% is a proxy for no detected </span><span class="c12">CD19</span><span class="c12">&#120491;exon2. We found that increased proportions of the </span><span class="c12">CD19</span><span class="c12">&#120491;exon2 splice variant is more common among B cells in DLBCL patients compared with health blood and spleen, indicating that the alternative splicing event is present in </span><span class="c12">approximately half of the patients</span><sup><a href="#cmnt22" id="cmnt_ref22">[v]</a></sup><sup><a href="#cmnt23" id="cmnt_ref23">[w]</a></sup><sup><a href="#cmnt24" id="cmnt_ref24">[x]</a></sup><sup><a href="#cmnt25" id="cmnt_ref25">[y]</a></sup><sup><a href="#cmnt26" id="cmnt_ref26">[z]</a></sup><sup><a href="#cmnt27" id="cmnt_ref27">[aa]</a></sup><span class="c12">&nbsp;before CAR therapy. The PSI of B-ALL patients resembled the healthy samples more closely, though the splice variant was still present in two thirds of the samples we analyzed </span><span class="c12">(</span><span class="c15 c12">Figure 3</span><span class="c12">)</span><span class="c1 c12">.</span></p><p class="c11 c35"><span class="c8 c23 c6"></span></p><p class="c27"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 602.00px; height: 601.01px;"><img alt="" src="images/image2.png" style="width: 602.00px; height: 602.00px; margin-left: 0.00px; margin-top: -0.49px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><sup><a href="#cmnt28" id="cmnt_ref28">[ab]</a></sup><span class="c44 c23 c15 c6">&nbsp;</span></p><p class="c11"><span class="c15">Figure</span><span class="c15">&nbsp;3</span><sup><a href="#cmnt29" id="cmnt_ref29">[ac]</a></sup><span>. </span><span>Histograms of the percent of CD19 transcripts that contain exon2 in healthy blood and spleen samples as well as DLBCL samples from the SRA database and B-ALL samples from </span><span>iCOPE</span><span class="c1">.</span></p><p class="c11 c35"><span class="c1 c12"></span></p><h2 class="c52" id="h.hikbkc31pte7"><span class="c41 c23 c40 c6">Discussion</span></h2><p class="c39"><span class="c1">CD19-directed CAR-T therapy has transformed the treatment landscape for refractory B-cell malignancies, but relapse remains a major limitation for long-term disease control. The present study identifies exon 2 skipping in CD19 as a potential correlate of relapse after CD19 CAR-T therapy and provides a structural and transcriptomic framework for its evaluation as a measurable biomarker candidate. </span></p><p class="c39"><span class="c1">Using computational structural modeling, we find strong indications that exon 2 exclusion destabilizes the epitope region recognized by the FMC63-derived CAR fragment, consistent with a mechanism of reduced antigen stability rather than primary sequence epitope loss. Because the pLDDT scores are based on predicted structures, they represent approximations of conformational stability rather than experimentally resolved data. The interpretation of pLDDT scores should therefore be considered as indicative of relative confidence in local folding rather than a direct biophysical measure of instability. </span></p><p class="c39"><span class="c1">In a small publicly available cohort of CD19 CAR-T&ndash;treated B-ALL patients, we observed that pre-treatment exon 2 skipping, quantified by the percent spliced in (PSI) of exon 2, was most pronounced in a patient who relapsed after 1.5 months and absent in a complete responder. Low-level exon 2 skipping was further detectable across both malignant and normal B-cell populations, indicating that this splicing event is physiologically tolerated at homeostasis but potentially exploitable as a biomarker for CD19 CAR-T therapy.</span></p><p class="c39"><span class="c1 c21">MISSING COHORT RESULTS</span></p><p class="c33"><span class="c1">Our results support and extend previous studies linking CD19 alternative splicing to CAR-T therapy resistance [xx&ndash;xx]. Earlier work has primarily focused on post-treatment emergence of the CD19&Delta;exon2 splice variant as a mechanism of antigen escape in B-ALL, while our analysis shows that CD19&Delta;exon2 is already present at low levels prior to therapy. This finding suggests that the presence of pre-treatment CD19&Delta;exon2 combined with a potent selective pressure, such as that exerted by CAR-T therapy, could be a cause of target loss. The observation that exon 2 skipping is more variable in DLBCL than in B-ALL or healthy B-cell&ndash;rich tissues may have direct translational relevance, as CD19 CAR-T therapy continues to expand into DLBCL and other lymphoma indications.</span></p><p class="c33"><span class="c1">Several limitations should be noted. First and foremost, the small number of CAR-T&ndash;treated patient samples precludes statistical analysis and prevents definitive conclusions regarding causality or predictive value. Read coverage in post-treatment samples was sparse, reflecting effective B-cell depletion, which limits quantification of splicing dynamics over time. Moreover, the PSI metric used here provides a proxy for exon 2 skipping rather than direct transcript-level quantification. An additional limitation of bulk RNA-seq data is that it cannot resolve whether CD19&Delta;exon2 transcripts are uniformly co-expressed with canonical CD19 within the same cells or confined to distinct subclones. If exon 2 skipping occurs stochastically across all B cells, selective pressure from CAR-T therapy would likely have limited impact on overall CD19 expression. However, if a subpopulation preferentially or exclusively expresses CD19&Delta;exon2, such cells could evade recognition and expand under therapeutic pressure. Current single-cell and long-read sequencing technologies are beginning to address this question, but their sensitivity is insufficient to reliably detect the low-abundance exon 1&ndash;3 splice junction in complex tissues. Likewise, the structural analyses rely on computational modeling and confidence scoring, which, while informative, require experimental validation to confirm conformational effects on the FMC63 epitope. Future studies incorporating targeted long-read sequencing, isoform-specific qPCR, or biophysical characterization of CD19 variants in larger CD19 CAR-T cohorts prior to treatment could validate these observations and distinguish between stable isoforms and transient splicing intermediates. Despite these constraints, the consistency between structural predictions, patient-level RNA patterns, and baseline tissue distributions strengthens the biological plausibility of the findings.</span></p><p class="c33"><span class="c1">From a translational perspective, the detection of exon 2 skipping at the mRNA level offers a feasible route for biomarker development. Because most CD19 CAR-T candidates undergo RNA sequencing during pre-treatment profiling, exon 2 PSI could be computationally inferred as an additional feature without extra experimental cost. Alternatively, qPCR assays targeting exon&ndash;exon junctions could provide a rapid and inexpensive diagnostic test to stratify relapse risk or monitor splicing changes during follow-up. Larger, prospective studies will be required to establish whether CD19 exon 2 skipping is merely a correlate of poor response or a functional determinant of resistance. Either outcome would enhance understanding of CD19 biology and contribute to optimizing CAR-T patient selection and monitoring.</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c11 c35"><span class="c1"></span></p><p class="c11"><span class="c1 c12">We need to discuss:</span></p><p class="c11"><span class="c1 c12">Structure predictions, Ab binding</span></p><p class="c11 c35"><span class="c1"></span></p><p class="c11"><span class="c12">In this study, we investigated the pre-treatment prevalence of the CD19&#120491;exon2 splice variant as a potential prognostic biomarker for relapse risk in R/R B-ALL and R/R DLBCL patients. CD19&#120491;exon2 has previously been observed prior to CART-19 therapy </span><span class="c12 c6 c19"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tHILyZ&amp;sa=D&amp;source=editors&amp;ust=1761295508909617&amp;usg=AOvVaw3soRuL8BjyA4AAz8Y28J9K">[41]</a></span><span class="c12">&nbsp;and is associated with a heightened risk of relapse </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?baAV74&amp;sa=D&amp;source=editors&amp;ust=1761295508909998&amp;usg=AOvVaw3ifK5mUPztk69OfFApOFSa">[35,36]</a></span><span class="c1 c12">. &nbsp;Upon predicting the structural impact of exon 2 deletion, we observed that its absence reduces the predicted stability of the protein, which may negatively impact antibody-antigen binding affinity. Additionally, although inconclusive, the small Zhang et al. cohort indicated that the prevalence of CD19&#120491;exon2 has predictive value for therapy success.</span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">To leverage the predictive value of CD19&#120491;exon2, the splice variant should be expressed prior to treatment. CD19&#120491;exon2 is as prevalent in B-ALL patients as in healthy blood samples, </span><span class="c12">which suggests that the splice variant is not disease-induced but rather present prior to CAR treatment</span><span class="c1 c12">. On the other hand, the DLBCL patients showed a higher prevalence of CD19&#120491;exon2 splice variants, indicating disease-induced alternative splicing events, prior to CAR treatment, warranting further analysis.</span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">In B-ALL, CD19-targeted therapies are currently being tested and implemented as a part of first line therap</span><span class="c12">y</span><span class="c12">&nbsp;</span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?S29eef&amp;sa=D&amp;source=editors&amp;ust=1761295508912234&amp;usg=AOvVaw3CDtQzDA2u5UE81yY1uzav">[70]</a></span><span class="c12">. The early addition of CD19-targeted therapies in B-ALL allows for concomitant de-intensification of the widely used combination chemotherapeutics, potentially reducing treatment-related mortality, which is currently around </span><span class="c12">4</span><span class="c12">% </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?mnb9oj&amp;sa=D&amp;source=editors&amp;ust=1761295508912756&amp;usg=AOvVaw1dM6rNP54vLoDBXY4WJ4ek">[59]</a></span><span class="c1 c12">. However, this prompts the need for improved stratification of patients based on biomarkers for the therapeutic efficacy of the CD19-targeted therapies. </span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">O</span><span class="c12">ur results carefully suggest that screening for the presence and frequency of CD19 splice variants can help </span><span class="c12">predict relapse risk after </span><span class="c12">CD19-targeted therapy</span><span class="c12">, although a larger study of patients </span><span class="c12">linking to clinical outcome </span><span class="c12">is needed for validation. A screening approach</span><span class="c12">&nbsp;would aim to identify high-risk individuals who may benefit more from clinical trial inclusion than costly therapies with a high risk of relapse. </span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">In a patient screening procedure, the full etiology of CART-19 resistance should be accounted for. Focusing solely on exon2 can prove limited, as CD19&#120491;exon2 might coexist alongside functional full-length CD19 </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1svlpq&amp;sa=D&amp;source=editors&amp;ust=1761295508914452&amp;usg=AOvVaw1eMjyHoD1q9t0dWo5RDgpl">[71]</a></span><span class="c12">, which could give false negative </span><span class="c12">signals</span><span class="c12">. Additionally, pre-treatment screenings might not always be informative, as some genetic variations in the CD19 gene and loss of heterozygosity might only manifest post-therapy </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?aB8shm&amp;sa=D&amp;source=editors&amp;ust=1761295508914976&amp;usg=AOvVaw1ghlcd21izR7bz9xHD3T1w">[42]</a></span><span class="c1 c12">. </span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">Adding to the complexity, other splicing events, such as intron2 retention, are also associated with therapy resistance </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?0VnxVR&amp;sa=D&amp;source=editors&amp;ust=1761295508915439&amp;usg=AOvVaw0Kri134wI9D09pD0Hv2PdQ">[37,54]</a></span><span class="c12">. In support of this notion, Figure 2 in this study shows similar indications where only the patient with complete remission (Patient D) lacked intron2 </span><span class="c12">retention</span><sup><a href="#cmnt30" id="cmnt_ref30">[ad]</a></sup><span class="c1 c12">. Further analysis of more samples is necessary to accurately attribute the lack of therapy response.</span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">In addition to improved risk stratification, new therapeutic approaches can help overcome the challenges of CD19 target loss. Emerging dual- and tri-target CAR therapies have shown promising results in overcoming relapse. These therapies appeared in reaction to the high relapse rate after anti-CD19 CAR T-cell therapy, recognizing the need for another target to prevent treatment resistance. Other evaluated markers include CD20, CD22, CD79a/b, CD123, CD10, CD38, and CD45 </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?1cqS5K&amp;sa=D&amp;source=editors&amp;ust=1761295508917008&amp;usg=AOvVaw1BPEvjLPsLfvcW_vEJPKr1">[10]</a></span><span class="c12">. Particularly, CD20 </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?N5LVh1&amp;sa=D&amp;source=editors&amp;ust=1761295508917254&amp;usg=AOvVaw05qyjfQGoQNxg5VVRC9GJW">[72,73]</a></span><span class="c12">, CD22 </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?pVHHg6&amp;sa=D&amp;source=editors&amp;ust=1761295508917563&amp;usg=AOvVaw3zK0xE_UhY3DndNqKf2z56">[19,42,72,74&ndash;76]</a></span><span class="c12">, CD123 </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?YFKJ8T&amp;sa=D&amp;source=editors&amp;ust=1761295508917734&amp;usg=AOvVaw0FAjJW7ZsihqyD1Vo5_JZc">[77]</a></span><span class="c12">, and CD79a/b </span><span class="c19 c12 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?BHHTwk&amp;sa=D&amp;source=editors&amp;ust=1761295508917899&amp;usg=AOvVaw1xeo6u-4HBbsW4iGktBAzk">[78,79]</a></span><span class="c1 c12">&nbsp;appear effective as additional targets.</span></p><p class="c11 c35"><span class="c1 c12"></span></p><p class="c11"><span class="c12">U</span><span class="c12">ntil then, we propose investigating the value of CD19 splice variant detection for early prediction of relapse risk prior to CART-19 therapy.</span><span class="c1 c12">&nbsp;Predicting relapse risk could help tailor the treatment pathway, guiding high-risk patients toward dual-target CAR clinical trials and away from the potentially ineffective standard CD19-directed therapy. We advocate actions to improve outcomes and reduce therapy expenses before, not after, the failure of current options.</span></p><p class="c11 c35"><span class="c8 c23 c12 c6"></span></p><p class="c11 c35"><span class="c8 c23 c12 c6"></span></p><sup><a href="#cmnt31" id="cmnt_ref31">[ae]</a></sup><sup><a href="#cmnt32" id="cmnt_ref32">[af]</a></sup><sup><a href="#cmnt33" id="cmnt_ref33">[ag]</a></sup><sup><a href="#cmnt34" id="cmnt_ref34">[ah]</a></sup><sup><a href="#cmnt35" id="cmnt_ref35">[ai]</a></sup><p class="c26"><span class="c23 c40 c12 c6 c49"></span></p><h2 class="c51 c17" id="h.ouqyrtma5twq"><span class="c36 c15 c12 c64">Kept here to save references. </span><span class="c8 c12">we analyzed the prevalence of CD19&#120491;exon2 pre- and post-treatment in a small cohort of R/R B-ALL patients and compared the CD19&#120491;exon2 prevalence to the CART-19 therapy outcome. To investigate why CD19 lacking exon 2 might evade antibody binding, we generated in silico 3D models of CD19 and CD19&#120491;exon2 with and without the FMC63 antibody. Looking at their respective confidence scores gives clues to their stability </span><span class="c8 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?tSM7WB&amp;sa=D&amp;source=editors&amp;ust=1761295508919874&amp;usg=AOvVaw0EvXQdH5uRVBVRhJeSfJbG">[51]</a></span><span class="c8 c12">. Similarly, the confidence score of the antibody:antigen complex provides indications for the</span><span class="c8 c12">&nbsp;binding affinity</span><sup><a href="#cmnt36" id="cmnt_ref36">[aj]</a></sup><span class="c8 c12">&nbsp;</span><span class="c8 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LpPufl&amp;sa=D&amp;source=editors&amp;ust=1761295508920244&amp;usg=AOvVaw1IZ7oVyeyhBMG3KM-cEt9r">[52]</a></span><span class="c8 c12">. Finally, computing the pseudo-perplexity provides a proxy for protein fitness measures like stability-based assays </span><span class="c8 c12"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?f3YL5V&amp;sa=D&amp;source=editors&amp;ust=1761295508920532&amp;usg=AOvVaw2rKkWuZRdbxJ1gA_ebDEtZ">[53]</a></span><span class="c8 c23 c12 c6">.</span></h2><h2 class="c17 c51" id="h.6hn8oy6nyp70"><span class="c8 c12">The reduced confidence scores and pseudo-perplexity indicate that exon 2 contributes to the overall structural integrity of CD19, and its deletion could destabilize the FMC63 antibody binding.</span><hr style="page-break-before:always;display:none;"></h2><h2 class="c52" id="h.pk8wmft33juz"><span class="c23 c40 c6 c41">Acknowledgments</span></h2><p class="c11 c35"><span class="c1"></span></p><h2 class="c52" id="h.q2hluknr6x53"><span>Author contributions</span></h2><p class="c11"><span class="c1">MBB, KVS, and LRO conceptualized the work. LRO and SHD designed the study. SHD, SM, KW, AN, KS contributed to data acquisition. SHD, GM, and MHH analyzed the data. All authors contributed to the interpretation of the data. SHD wrote the manuscript. All authors critically reviewed and approved of the final version of the manuscript.</span></p><h2 class="c52" id="h.dgaatfchkj2s"><span>Conflict of interest</span></h2><p class="c11"><span class="c1">The authors declare no competing interests.</span></p><h2 class="c52" id="h.m1o5igbkjn6z"><span>Code availability</span></h2><p class="c11"><span>Code to replicate the analyses are available on GitHub: </span><span class="c19"><a class="c2" href="https://www.google.com/url?q=https://github.com/shdam/relapseR&amp;sa=D&amp;source=editors&amp;ust=1761295508922595&amp;usg=AOvVaw2klttuKp_10kBqBGvVWrfM">https://github.com/shdam/relapseR</a></span><span class="c1">&nbsp;</span></p><h2 class="c52" id="h.m66tc9oizsh"><span>Data availability</span></h2><p class="c27"><span class="c8 c17">Data from </span><span class="c8 c18 c17">snapcount</span><span class="c8 c17">&nbsp;compilations are available through the </span><span class="c8 c18 c17">snapcount </span><span class="c8 c17">R package, as used in this study. Data from the CART-19-treated B-ALL cohort is available from Zhang et al. </span><span class="c8"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?yvtnio&amp;sa=D&amp;source=editors&amp;ust=1761295508923264&amp;usg=AOvVaw0ny4Mjy3QNxMgKLA-WlORI">[12]</a></span><span class="c8 c17">. </span><span class="c8 c21">Data from the treatment na&iuml;ve B-ALL cohort</span><span class="c8 c21">&nbsp;is available upon request ?? </span><span class="c8 c23 c21 c6">Karin, please advise on appropriate wording.</span></p><p class="c26"><span class="c49 c23 c40 c6"></span></p><h2 class="c51 c69 c17" id="h.ki9pk5x18beg"><span class="c42 c23 c15 c6"></span></h2><h2 class="c52" id="h.z684a7sja8o1"><span class="c41 c23 c40 c6">Supplementary Figures</span></h2><p class="c11"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 429.50px; height: 368.86px;"><img alt="" src="images/image3.png" style="width: 429.50px; height: 368.86px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><sup><a href="#cmnt37" id="cmnt_ref37">[ak]</a></sup><sup><a href="#cmnt38" id="cmnt_ref38">[al]</a></sup><sup><a href="#cmnt39" id="cmnt_ref39">[am]</a></sup><sup><a href="#cmnt40" id="cmnt_ref40">[an]</a></sup><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 601.70px; height: 421.33px;"><img alt="" src="images/image1.png" style="width: 601.70px; height: 421.33px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c11"><span class="c20 c15">Figure </span><span class="c20 c15">S1</span><sup><a href="#cmnt41" id="cmnt_ref41">[ao]</a></sup><span class="c15 c20">.</span><span class="c8">&nbsp;</span><span class="c20 c40">Bar charts of reductions in mean AlphaFold confidence (pLDDT) and relative pseudo-perplexity. AbAG: Antibody:antigen complex.</span></p><hr style="page-break-before:always;display:none;"><h2 class="c51 c17 c69" id="h.iyt1shx9onao"><span class="c23 c15 c6 c42"></span></h2><h2 class="c51 c17" id="h.gyocezfw3p43"><span class="c15 c61">References</span></h2><p class="c31 c35"><span class="c30 c23 c17 c6"></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925085&amp;usg=AOvVaw3WuomBo5bWAHCJq7XuH8FA">1. Zhang X, Lu XA, Yang J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925199&amp;usg=AOvVaw0Lf5w5cV4ZYghpU_gVlz4e">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925479&amp;usg=AOvVaw3nOteDZ1FQzT1GC4e1XspV">&nbsp;Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925566&amp;usg=AOvVaw2i4d1UcUx9E42xj50EA3_B">Blood Adv</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925647&amp;usg=AOvVaw12Pv0tADi8VCkSedfQ4bPK">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925719&amp;usg=AOvVaw2DFYX9vZVO9jYDvN7ChJRR">4</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508925811&amp;usg=AOvVaw0l-B6soC-N5U0Q_fZP_9G8">:2325&ndash;38.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926020&amp;usg=AOvVaw3VJ8PWpR28N6IJdPAXG_VH">2. Lee DW, Kochenderfer JN, Stetler-Stevenson M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926103&amp;usg=AOvVaw2RY26eNNxM_cyw2Uv56Thd">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926404&amp;usg=AOvVaw0IivHZ07-yUtYy9P_N2Uak">&nbsp;T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926505&amp;usg=AOvVaw069hKtRUGjEWnEz0nT4GtL">Lancet Lond Engl</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926587&amp;usg=AOvVaw2N-z_ujLtfBas8asTMiV6h">&nbsp;2015;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926666&amp;usg=AOvVaw3mD-2IQP5lpapWdiwsO3M5">385</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926752&amp;usg=AOvVaw0tC5-EJ73RHdrVH97WijkF">:517&ndash;28.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508926977&amp;usg=AOvVaw2G9A4iOxJq0SDfa2HVNYel">3. Maude SL, Frey N, Shaw PA </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927093&amp;usg=AOvVaw1DEkWt8PDIeK2xPejVb9ac">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927293&amp;usg=AOvVaw1Je5KuzYBFRhbdjm3nP82r">&nbsp;Chimeric antigen receptor T cells for sustained remissions in leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927386&amp;usg=AOvVaw20qIigohboPjnn1UAWwPYO">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927472&amp;usg=AOvVaw2CXkseE8v51RkzeyvH-5fG">&nbsp;2014;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927549&amp;usg=AOvVaw1dE0CbDhP1WUnTofA4SU_q">371</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927634&amp;usg=AOvVaw2oV9Iy1r41zTPT32RfnniU">:1507&ndash;17.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927815&amp;usg=AOvVaw2t1jTx4Y8YXtQ3IDTYg14Y">4. Park JH, Rivi&egrave;re I, Gonen M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508927945&amp;usg=AOvVaw3v-REe2ZgivQWYF2vykulc">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928142&amp;usg=AOvVaw3yLqg9Fum-PE7PUZuS1z-s">&nbsp;Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928267&amp;usg=AOvVaw32mHOkhD4X6T_Ux_4HRpx1">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928359&amp;usg=AOvVaw2wf64iQ3aCe2QXXLxRAtnZ">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928442&amp;usg=AOvVaw35p6K5mGUPHzI0ZJWIHJaf">378</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928536&amp;usg=AOvVaw1Vxufp9SZSEx02YXKoNtNL">:449&ndash;59.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928748&amp;usg=AOvVaw2oAXYzOpDySPdSYe30UHyM">5. Turtle CJ, Hanafi LA, Berger C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508928835&amp;usg=AOvVaw0AEbmOGTpibXdQiiUIii-N">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929027&amp;usg=AOvVaw2dbWgd5Dxyh92We0a5E-48">&nbsp;CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929117&amp;usg=AOvVaw3qEA4uPBdefKdaDDLB5f9q">J Clin Invest</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929209&amp;usg=AOvVaw3s1ItYVJonpjS5bUZjwiab">&nbsp;2016;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929289&amp;usg=AOvVaw1WZOwXkGyU1p3obvMTISnB">126</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929389&amp;usg=AOvVaw2yFt050zGnemrFevIpLFiW">:2123&ndash;38.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929607&amp;usg=AOvVaw3b4pqZf4--vM5uQRuuAnrF">6. Cao J, Wang G, Cheng H </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508929694&amp;usg=AOvVaw2WCoQRXUaAiADhgjt2ZVD7">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930031&amp;usg=AOvVaw1IN-7r4irE_phmy7wkmsVE">&nbsp;Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930124&amp;usg=AOvVaw0jIzRcg6FqYgSSuQpVxX2s">Am J Hematol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930210&amp;usg=AOvVaw17FdRSRWcapfLSU2a4hRtS">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930314&amp;usg=AOvVaw0fS2FLgr2b5CmWW8UhpAYi">93</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930401&amp;usg=AOvVaw0psm_UrcKNB5l4TTDjr9N9">:851&ndash;8.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930603&amp;usg=AOvVaw2iiL_F0ynS7siwhHpLdnrq">7. Di Blasi R, Le Gouill S, Bachy E </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930717&amp;usg=AOvVaw2u5U9szoSv9MdTrSB-5DCQ">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508930991&amp;usg=AOvVaw2TJxCRMv9SPoyijPnXUAWW">&nbsp;Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931091&amp;usg=AOvVaw0PM9CQ-X6zZ-tU-900zB1K">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931199&amp;usg=AOvVaw1MACjgDJyoI7cCmqUZ9Tjq">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931282&amp;usg=AOvVaw3OSj2LZLOFwJTzaNa6-KC8">140</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931394&amp;usg=AOvVaw0qGOJm2huzIuf2U2bWeIdo">:2584&ndash;93.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931607&amp;usg=AOvVaw227b7iiHx3B-d4cGoAXqvW">8. Gardner RA, Finney O, Annesley C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931690&amp;usg=AOvVaw0mG7im56L1dBr9c3LOFEaA">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508931964&amp;usg=AOvVaw0BPF34LYZJ3QUfzQFBjjOV">&nbsp;Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932044&amp;usg=AOvVaw2L4yZlhYWswALU7erYzu8P">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932133&amp;usg=AOvVaw15iBTDpFJnPkBzMyHxW7s1">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932225&amp;usg=AOvVaw3g9jRoNjeDnYHw_4vDtxo3">129</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932320&amp;usg=AOvVaw3kXAx366a5VcKfnueR0zeQ">:3322&ndash;31.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932526&amp;usg=AOvVaw260XT7uI3HLRjkrbHWxaBF">9. Li S, Zhang J, Wang M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932613&amp;usg=AOvVaw2byDc7Tg5mVD4PkacPyR2m">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932859&amp;usg=AOvVaw2GXPnQrmcnrrgLzWe7SM3Y">&nbsp;Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508932949&amp;usg=AOvVaw0ERfGQkDFETN5ssrt-NOKe">Br J Haematol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933030&amp;usg=AOvVaw2o8VYjWinpKc89Bob1RiaU">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933107&amp;usg=AOvVaw3CQ3NYXebkmzH1wVE2TwmY">181</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933191&amp;usg=AOvVaw1ddPBexH2D8lVJbuzBmHL1">:360&ndash;71.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933373&amp;usg=AOvVaw2xDoSxv9ncpbwzF_puVHq9">10. Xu X, Sun Q, Liang X </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933498&amp;usg=AOvVaw1NGmjyK18TJrGj6PrXTXER">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933861&amp;usg=AOvVaw21sByYH3VFqczAnRl5INEs">&nbsp;Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508933977&amp;usg=AOvVaw2Z9yHzEkjhIV2WnqF82aHo">Front Immunol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934066&amp;usg=AOvVaw2LWwAZCqrAdZFS0KOahZu9">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934166&amp;usg=AOvVaw3dhnk2QR76tWUJNxBICYN-">10</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934270&amp;usg=AOvVaw0Nx5F1vYUoLVCIbyPxADs1">:495638.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934496&amp;usg=AOvVaw04iRZ94cjyZsB6wgusIq_G">11. Maude SL, Laetsch TW, Buechner J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934583&amp;usg=AOvVaw0-ZxWErPxXisB0zdyQB_jq">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934803&amp;usg=AOvVaw3imaC3hz2PC_UgrVYzU200">&nbsp;Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934896&amp;usg=AOvVaw0j6oT4uzg9Qt-A2wdYSpD7">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508934978&amp;usg=AOvVaw3aPjMbcYxlKHrP9jcgfnsf">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935054&amp;usg=AOvVaw3B2LuR8cjTglNvIoOdR_0L">378</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935139&amp;usg=AOvVaw3uIG2wO9E8m576DoqMXO2r">:439&ndash;48.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935325&amp;usg=AOvVaw1NQKdDnd-b3Kny29fBpH66">12. Zhang Q, Hu H, Chen SY </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935427&amp;usg=AOvVaw3H3zC-1qeCk277j7ZSvh55">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935635&amp;usg=AOvVaw2CSkW4Buy4J8Y-YtH1XgI_">&nbsp;Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935762&amp;usg=AOvVaw3mk3ZQa6YJ79Z3lRFQUXGv">Genomics Proteomics Bioinformatics</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935864&amp;usg=AOvVaw0ZHewtlAKOIgp4j1IDrDsK">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508935999&amp;usg=AOvVaw2OC5DMAWGJYV6ywhl1QLK-">17</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936098&amp;usg=AOvVaw32UWipraZHPyD1-adPWBg3">:190&ndash;200.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936308&amp;usg=AOvVaw1qlxpwsisK1OT7L4yjSZ57">13. Frontzek F, Karsten I, Schmitz N </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936392&amp;usg=AOvVaw3gxk83TSxpRGrFwHkQzvQ8">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936654&amp;usg=AOvVaw3rFPzDsrMf3NOti1Jco4-g">&nbsp;Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936780&amp;usg=AOvVaw3Ds5VVyKjU-Kxe9wYMB6du">Ther Adv Hematol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936893&amp;usg=AOvVaw1ddnmoOZ6BOTDIsis4wSay">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508936994&amp;usg=AOvVaw09NikiE_XNuKjDQuMHGaBk">13</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937116&amp;usg=AOvVaw0XaKFQQSkcQOO4-HBC82eK">:20406207221103321.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937357&amp;usg=AOvVaw1LM9Uy-pyxkU45V95otZnc">14. Schuster SJ, Bishop MR, Tam CS </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937449&amp;usg=AOvVaw33qIiBPoY5ROpo7bc7nbWP">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937644&amp;usg=AOvVaw3AQbh4bXfbmHdbFbqvQ1XA">&nbsp;Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937735&amp;usg=AOvVaw0aKWh5oDFD_G2tw8ErcIbn">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937815&amp;usg=AOvVaw2vhO6zX77mrMxUn9sYl3J2">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937891&amp;usg=AOvVaw1Fij65IqNFAcU_snZNDLhY">380</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508937974&amp;usg=AOvVaw04_sXsx-RbVcYJ4fqmtJlI">:45&ndash;56.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938260&amp;usg=AOvVaw1xkR6CG-TXGkHFjzdwtCMT">15. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938344&amp;usg=AOvVaw00ceLbzYOtnxUd4se42tvW">Nat Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938425&amp;usg=AOvVaw1CkPrSpXSPyekgRoNB9ND9">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938506&amp;usg=AOvVaw2hbLsPbTIa6MYfVtQAb5kU">25</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938591&amp;usg=AOvVaw2IrwT5a7jxSZKQMzVM39SY">:1341&ndash;55.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938787&amp;usg=AOvVaw02e9BW11bvGPpcBlqiBjZb">16. Grupp SA, Kalos M, Barrett D </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508938871&amp;usg=AOvVaw02uC1LS60aMy61iE8aq294">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939101&amp;usg=AOvVaw2kWahtauDVuRzEAi9vGv93">&nbsp;Chimeric Antigen Receptor&ndash;Modified T Cells for Acute Lymphoid Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939200&amp;usg=AOvVaw2LMOMBLcxBDeAR5b7W6BbF">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939289&amp;usg=AOvVaw3111JiZ9txmp2VorrvfaMf">&nbsp;2013;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939384&amp;usg=AOvVaw25SDvf7vcz2bAJlB8WZiFH">368</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939508&amp;usg=AOvVaw04xuJsb1oCw-V6tj7TvXOB">:1509&ndash;18.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939850&amp;usg=AOvVaw2sXlLmOSkxQrQWmBd3mLnd">17. Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508939983&amp;usg=AOvVaw3JwxP3NONUL8fX-DgRpNN5">Curr Res Transl Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940066&amp;usg=AOvVaw0JrpwLVnw7vcWqiBJKtMV2">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940158&amp;usg=AOvVaw0_w1uyDxbxwfegWD_cFiqM">66</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940244&amp;usg=AOvVaw1pXUXBbkxZ3Yy5x8oi2wH6">:50&ndash;2.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940451&amp;usg=AOvVaw0p_5TtBohKevGwKpyI7j2n">18. Bonifant CL, Jackson HJ, Brentjens RJ </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940534&amp;usg=AOvVaw2yYdS_whtfp9KP3Qpqcc60">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940678&amp;usg=AOvVaw0KuOrpOABPz8nPrE0GF6U0">&nbsp;Toxicity and management in CAR T-cell therapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940778&amp;usg=AOvVaw0VitIb17F9VRX9xJtrEWCf">Mol Ther - Oncolytics</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940857&amp;usg=AOvVaw1uEntTIsNc9UKD1G54mXFO">&nbsp;2016;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508940932&amp;usg=AOvVaw2VSpkdUDxfyCb8Df4FdFBi">3</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941032&amp;usg=AOvVaw1BPfiLPjLQQblbdXpzQ6r9">:16011.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941211&amp;usg=AOvVaw3oc9cU_v7jMfH-njirfXqZ">19. Yang J, Li J, Zhang X </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941294&amp;usg=AOvVaw2q4YgMZI_gzF3kpVIlun_r">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941593&amp;usg=AOvVaw3h9-iAvqTheDy5UzayaqlL">&nbsp;A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941673&amp;usg=AOvVaw0lkCTUO_ZtLqYfud0YFDp3">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941752&amp;usg=AOvVaw39U-BMjsgmi_o3WpWetwUU">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941827&amp;usg=AOvVaw1sPEYHxOw3GcQUGZAxMEPQ">132</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508941914&amp;usg=AOvVaw2t4PEpr7Ek0PZix1bpjMnM">:277&ndash;277.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942122&amp;usg=AOvVaw0-3q27WWsNHUIRa7MxEh6S">20. Davila ML, Riviere I, Wang X </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942209&amp;usg=AOvVaw14hR1lHrODEpdvUaGI92yH">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942438&amp;usg=AOvVaw0OI-C7lfay7JNJkcvcANmM">&nbsp;Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942531&amp;usg=AOvVaw05b1xBdi6AuO_rIAR7bZWS">Sci Transl Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942625&amp;usg=AOvVaw3KHiPJP5m8vwN3Jy4mewkD">&nbsp;2014;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942725&amp;usg=AOvVaw2mDeebErBuFsxyA83GIp56">6</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508942871&amp;usg=AOvVaw02for8SeANbkEFVc_bahhT">, DOI: 10.1126/SCITRANSLMED.3008226.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943061&amp;usg=AOvVaw1XO184JKgWpfIW3r2KFtXB">21. Nguyen K, Devidas M, Cheng SC </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943144&amp;usg=AOvVaw2EZnSx5eC_JzFql9S_tSze">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943393&amp;usg=AOvVaw1CJp5cHUvAbiPHHTdaUE0v">&nbsp;Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children&rsquo;s Oncology Group study. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943483&amp;usg=AOvVaw0MvEa4SwLXUS6oqtbHxsKF">Leukemia</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943563&amp;usg=AOvVaw2Q5c55F3B4nuuORJR_xomi">&nbsp;2008;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943636&amp;usg=AOvVaw08fwUY-gVqdj2LtMatGzTX">22</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943740&amp;usg=AOvVaw3_YjKsO9ry7gDNnciAcPoU">:2142&ndash;50.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508943923&amp;usg=AOvVaw0zcoXwnbeUZ00SjIFHDSGL">22. Roddie C, Sandhu KS, Tholouli E </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944004&amp;usg=AOvVaw19I3SQ7Zfiku7vsT9VnYpk">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944191&amp;usg=AOvVaw04pkYHBum28M6jRV6lAuwv">&nbsp;Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944280&amp;usg=AOvVaw0T8Lc0bU5ePQ8mcNItjmsS">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944358&amp;usg=AOvVaw0sl16voYFHeIEUJxSdhzPo">&nbsp;2024;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944438&amp;usg=AOvVaw2w6M8wVPuly72JDl0OGh9C">391</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944524&amp;usg=AOvVaw1FcEMa7ucQN-OnlGml-LG-">:2219&ndash;30.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944790&amp;usg=AOvVaw146RkH8y6_Un_Sxgm7eF6T">23. Abramson JS, Palomba ML, Gordon LI </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508944899&amp;usg=AOvVaw37HGUZkvNlJBde6LvES8tf">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945217&amp;usg=AOvVaw0stMu_fnjA0fXAOyUQSwKB">&nbsp;Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945316&amp;usg=AOvVaw2iImBkk59K8tIXAavqT2oP">Lancet Lond Engl</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945396&amp;usg=AOvVaw2ErwkKlRV9Y5nn8TVz6DrB">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945488&amp;usg=AOvVaw04ulYpI-7nZ1Y9wy1ruyI3">396</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945573&amp;usg=AOvVaw2PUmVrEQUYu9Z-lEsq9qUG">:839&ndash;52.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945754&amp;usg=AOvVaw39oHodD6_wdwnPsh6oBZ-I">24. Bouchkouj N, Lin X, Wang X </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508945857&amp;usg=AOvVaw0rqv_b7eNuWk-7pmxxb6EC">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946197&amp;usg=AOvVaw0M2WTnB0RoHlVVzDJN310w">&nbsp;FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946320&amp;usg=AOvVaw2Gxx-RnewWnj3dSqkCkr8B">The Oncologist</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946417&amp;usg=AOvVaw1XzWfViUDhRQ6oSFgHO6Z_">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946511&amp;usg=AOvVaw2tggvehXfHWxif_SysFMYi">27</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946601&amp;usg=AOvVaw2HhbGfk608gig3b8qqbGpk">:892&ndash;9.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946790&amp;usg=AOvVaw1Md7vlc82Lo9Kxs-0i8nT7">25. Locke FL, Ghobadi A, Jacobson CA </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508946873&amp;usg=AOvVaw23pPeOEqdtjaT_v3lyPYDh">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947165&amp;usg=AOvVaw3d5DrAFjt6tsc7UyBYe-8m">&nbsp;Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947257&amp;usg=AOvVaw1c-uSlC6gqy1zahYROaBz3">Lancet Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947338&amp;usg=AOvVaw2t86Sw_fBAkLXwHmSGsDpO">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947412&amp;usg=AOvVaw28CFungEJ-rSnrZ_gKGN9J">20</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947500&amp;usg=AOvVaw3c--xddYlUZzozWuFSbA7m">:31&ndash;42.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947871&amp;usg=AOvVaw258tuMe4QwqkOZ4TiBlFAz">26. Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508947961&amp;usg=AOvVaw0_Tj2ErQxuXkz1CJRNl5vF">JAMA Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948059&amp;usg=AOvVaw0ZceenR-vJNIRr85T4loJm">&nbsp;2020;</a></span><span class="c6 c15"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948138&amp;usg=AOvVaw3WHv9mqiHGOQKrAbE2_k2x">6</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948229&amp;usg=AOvVaw237vVjkYUYDCqNJN1g_ve6">:281&ndash;90.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948465&amp;usg=AOvVaw0KBOepeLpvDM5k_CryaZHC">27. Bender JD, Damodharan S, Capitini CM </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948570&amp;usg=AOvVaw0SIisuiJEAPbJUBV5iY8se">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948841&amp;usg=AOvVaw3Wufj2Pi5JfY3v91tliaux">&nbsp;Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508948929&amp;usg=AOvVaw0EDlAsVoXGaFySeMNyi04u">Blood Adv</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949008&amp;usg=AOvVaw16f8fhGFVVqwfZvIH4LPDY">&nbsp;2024;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949080&amp;usg=AOvVaw2h8OddZeriXCao_xIsyEPS">8</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949168&amp;usg=AOvVaw2GKXoMvcXSDhxaEW-8TkHa">:4164&ndash;8.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949362&amp;usg=AOvVaw0j1bRdouA6G4kkvfBJt7Ja">28. Neelapu SS, Locke FL, Bartlett NL </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949463&amp;usg=AOvVaw2JPjD45g2kT-En9olXjUur">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949657&amp;usg=AOvVaw07sVRMfp6mI7FRMm0Q4ycU">&nbsp;Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949747&amp;usg=AOvVaw3vFeavglSdShlZQHSPv9RL">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949828&amp;usg=AOvVaw1raHrGpsl0-3ojw2U7TW5N">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508949915&amp;usg=AOvVaw3_606qkV-WxyD77cn3Qqmt">377</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950021&amp;usg=AOvVaw1ClL2Godvs1RUreEcJPeGs">:2531&ndash;44.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950227&amp;usg=AOvVaw1fda-6nWpQO3oVLov-9JbC">29. Pasquini MC, Hu Z-H, Curran K </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950335&amp;usg=AOvVaw3hb0tIjiLgSpPUqPo-y3I-">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950633&amp;usg=AOvVaw1PBXF5aln4Eo5m07DzVt3G">&nbsp;Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950723&amp;usg=AOvVaw3XovYaRL1o5oH2_1h3q3n3">Blood Adv</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950803&amp;usg=AOvVaw3l5RudodCgbPiypXwXqbFX">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950878&amp;usg=AOvVaw034_1xSmdYDaD41b3CDZsa">4</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508950968&amp;usg=AOvVaw2_yajzxj4jUt0xeaI2sSUX">:5414&ndash;24.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951152&amp;usg=AOvVaw1NFwGYN0N4HLyhZHgZsx9s">30. Nastoupil LJ, Jain MD, Feng L </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951236&amp;usg=AOvVaw0EHtS6O8p7f0EDDEl397DF">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951514&amp;usg=AOvVaw2WwTL5ZYPu4J3pm6t3W7SA">&nbsp;Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951639&amp;usg=AOvVaw0i9kZ17EdiJL6QOj3ZeO2I">J Clin Oncol Off J Am Soc Clin Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951721&amp;usg=AOvVaw15kgq8CjI_5DxxQPIG00EJ">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951795&amp;usg=AOvVaw356gYZi61K9ILbWe4z8dRl">38</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508951878&amp;usg=AOvVaw3Gr8BYAtP7Jv5FpFR3Z8Kp">:3119&ndash;28.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952062&amp;usg=AOvVaw1mR4oOStNwM4VyrDEc_6ht">31. Bethge WA, Martus P, Schmitt M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952157&amp;usg=AOvVaw1qCmzShtLg4nONRnu1oJ4e">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952403&amp;usg=AOvVaw3PebFrlXqmLLzkxlts-EDZ">&nbsp;GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952530&amp;usg=AOvVaw26tzFcRz4l1VPsqaZcWK7U">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952615&amp;usg=AOvVaw2MTT4VEalQlzPNhwFnmJ1h">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952693&amp;usg=AOvVaw2dKf0FKB6rP8moFU8J5uQW">140</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952776&amp;usg=AOvVaw0jY6PynNuBZCyi6MOCb70F">:349&ndash;58.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508952978&amp;usg=AOvVaw1MWGEwW_8nh3YkNHzwVSj6">32. Iacoboni G, Villacampa G, Martinez-Cibrian N </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953063&amp;usg=AOvVaw09MZTJ9u0bg9r6ucwqBhwn">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953316&amp;usg=AOvVaw3Ndr-JluIBoJoLEn3sa2X-">&nbsp;Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953405&amp;usg=AOvVaw25FS4Koi1MqVghhCkMwtUe">Cancer Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953488&amp;usg=AOvVaw2Sn6scHIf0t9UW8oZXnwQd">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953567&amp;usg=AOvVaw34NWG_FvJH6kDlalbLXsSs">10</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953664&amp;usg=AOvVaw0eBl08Vbbu76FOAWHLyr2q">:3214&ndash;23.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508953998&amp;usg=AOvVaw1tVFZAV43vtoRPNz2x1o22">33. Johnson GA, Locke FL. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954140&amp;usg=AOvVaw3n0rjIZiNRCIO-tLIaGC04">Hematol Oncol Clin North Am</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954282&amp;usg=AOvVaw3YeB9s83mOiBiVXZBzGFP1">&nbsp;2023, DOI: 10.1016/J.HOC.2023.07.003.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954508&amp;usg=AOvVaw2i9LIlJqLCP1_pC4B-eW4x">34. Nie Y, Lu W, Chen D </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954599&amp;usg=AOvVaw3baWrqijO5u7HBpELeZNV5">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954870&amp;usg=AOvVaw3ZrUMv-_nUlzKxu2CQaTUH">&nbsp;Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508954975&amp;usg=AOvVaw0cUmO2k1EtvKHRUML9KRPJ">Biomark Res 2020 81</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955054&amp;usg=AOvVaw3lQPH7f-qQS7tjRkoIbOkk">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955142&amp;usg=AOvVaw2lYxHOnJy2ino9rGVQu0Cr">8</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955226&amp;usg=AOvVaw2Ndn3iyegNYgT--78Lcbab">:1&ndash;17.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955409&amp;usg=AOvVaw1bqV-K-pgbOj7N8JbVxxTj">35. Sotillo E, Barrett DM, Black KL </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955501&amp;usg=AOvVaw2QCfiO8mlfzMcA-H9iPX4V">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955736&amp;usg=AOvVaw3NgmtWx2Vzu6ld5G-sa1fm">&nbsp;Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955826&amp;usg=AOvVaw2FRcPq4B2zH6t3QfQUb1lm">Cancer Discov</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955904&amp;usg=AOvVaw1l7U0RYdodawsDrp3qwm2k">&nbsp;2015;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508955974&amp;usg=AOvVaw2ulRdNja6HYPcFpe0Wdnl6">5</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956059&amp;usg=AOvVaw3eNo2aFmd1ibqYxn5SjcYQ">:1282&ndash;95.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956255&amp;usg=AOvVaw3lSTbLVO9H6i5MSwl8Zklw">36. Cort&eacute;s-L&oacute;pez M, Schulz L, Enculescu M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956337&amp;usg=AOvVaw3evdi5Nb7FXxIstVaHUL13">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956605&amp;usg=AOvVaw1xi1M-qje_CqixnrKhDAkE">&nbsp;High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956691&amp;usg=AOvVaw3LJ7q0BPuYleBCefX8xw6-">Nat Commun</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956769&amp;usg=AOvVaw2ZCUoY2QG--K_QFCydnv4F">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956842&amp;usg=AOvVaw3fBXj1Hrq0SBfN0CBR6GgI">13</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508956920&amp;usg=AOvVaw3X4ALr8bzD4d4nCdyz1B3r">:5570.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957098&amp;usg=AOvVaw1cRALM_ia1ZuHscqo_uVY7">37. Asnani M, Hayer KE, Naqvi AS </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957185&amp;usg=AOvVaw1ueVf312o2HKFLWSeSPK4b">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957429&amp;usg=AOvVaw2OumYgT6fTiVRmDa2u2yzS">&nbsp;Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957516&amp;usg=AOvVaw0xTpnfG67CRkrdUex0709Z">Leukemia</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957596&amp;usg=AOvVaw2n8Af7GDAz-vn9sb5wGcZH">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957668&amp;usg=AOvVaw13gj89w8r2n2GsH6UeKsA3">34</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957751&amp;usg=AOvVaw0aJUwN_1jQ0xhImtS4kXwi">:1202&ndash;7.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508957965&amp;usg=AOvVaw0n2slweW-LQ7_ZAzU16ZQp">38. Rabilloud T, Potier D, Pankaew S </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958072&amp;usg=AOvVaw3WOhQtUd9gKr3JZ4L6JWNU">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958401&amp;usg=AOvVaw0GFW-1TFqpAsKjTwKWuv8q">&nbsp;Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958496&amp;usg=AOvVaw3H4njdkpxEs1aTTeiqcmU0">Nat Commun</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958575&amp;usg=AOvVaw011ZzrSaFvfbWljA7o0-j8">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958648&amp;usg=AOvVaw1LYulV6a3oGHXie3wbsPsH">12</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958723&amp;usg=AOvVaw0Szd2EB_YrrLw_KEIhVIrT">:865.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958896&amp;usg=AOvVaw37pDGFliQqd2PSZfS4XIRL">39. Zhao Y, Aldoss I, Qu C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508958977&amp;usg=AOvVaw36WJLmlzrh_VmUithgjXRy">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959186&amp;usg=AOvVaw3Z413aUIxQAmPhQaHjJ7gf">&nbsp;Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959281&amp;usg=AOvVaw0gc2ZIHXrxK8n5S2m9o8Xv">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959360&amp;usg=AOvVaw2DBj6OcW7R_SOFGpTzFXzV">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959455&amp;usg=AOvVaw2JQIIj4eDk5tV_UAgmtjDo">137</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959540&amp;usg=AOvVaw02iCsxBoBlDysnXS1STdMF">:471&ndash;84.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959758&amp;usg=AOvVaw3jBFpB28WTxg2sJl2tPrcn">40. Bagashev A, Sotillo E, Tang C-HA </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508959844&amp;usg=AOvVaw0WboLGyYmcd-dCNYT9hTck">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960105&amp;usg=AOvVaw1jlyNaKtprcqKrqBQX-D5K">&nbsp;CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960197&amp;usg=AOvVaw1TK_ij-7U527_8pjBsnmgD">Mol Cell Biol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960278&amp;usg=AOvVaw0aao3EGMkBEXANg_LRtTRA">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960350&amp;usg=AOvVaw3RomkMekfgc_Y9OVgs8ijz">38</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960465&amp;usg=AOvVaw1vJ8kP2taUWhtoPygYa5Og">, DOI: 10.1128/MCB.00383-18.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960645&amp;usg=AOvVaw2evBLKg8mpYYKfa4potfwB">41. Fischer J, Paret C, El Malki K </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508960724&amp;usg=AOvVaw3h2tXLkIPlh_qHUVKL7m6i">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961017&amp;usg=AOvVaw2ANRANJcVLp3IeDHihtAEe">&nbsp;CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961112&amp;usg=AOvVaw3Cy8TRc4KIBsNGx0TmWsHg">J Immunother</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961234&amp;usg=AOvVaw0SiJWvpOMxHw424yDjUpc3">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961335&amp;usg=AOvVaw0W7c9IBNH3TKzI2uK6gmO2">40</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961458&amp;usg=AOvVaw1OqH2X-4PI91Gr0zRNTDzj">:187&ndash;95.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961730&amp;usg=AOvVaw0A7pHyq9tCmyfMXq7_jXSd">42. Orlando EJ, Han X, Tribouley C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508961821&amp;usg=AOvVaw10qWYVc0C0PhXttcxlirId">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962026&amp;usg=AOvVaw2ryzKOiDMONt4gDKBzGBwX">&nbsp;Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962121&amp;usg=AOvVaw2rYG0IKWswlHgTZ_9Y4Gwf">Nat Med 2018 2410</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962203&amp;usg=AOvVaw1JsQ8NBFZW_BNWrfki2UxW">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962278&amp;usg=AOvVaw1C7Hq4CbMtn_xHSzpfDdQ9">24</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962361&amp;usg=AOvVaw0c3XHUpFc14AWnpelpugAK">:1504&ndash;6.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962549&amp;usg=AOvVaw1ethi9JvWW9x5w69USs4j9">43. Hamieh M, Dobrin A, Cabriolu A </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962638&amp;usg=AOvVaw3ulQZ01e-Ms0Ua2XMiKmnQ">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962824&amp;usg=AOvVaw15_r6SaelD_luzDJE55fGd">&nbsp;CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508962902&amp;usg=AOvVaw2QYjroVVXQCOSCqpjHy1qF">Nature</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508963005&amp;usg=AOvVaw1xhJ9NmCvSQEu318YQtuL1">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508963113&amp;usg=AOvVaw3Mob_oXEvAQ-E-alHebMy4">568</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508963230&amp;usg=AOvVaw3ORvvxPH5zk7vhgiLYTpTt">:112&ndash;6.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508963479&amp;usg=AOvVaw226rk3_5LTmGvAnti41lgr">44. Jacoby E, Nguyen SM, Fountaine TJ </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508963692&amp;usg=AOvVaw2ri83GifMkKgFPpKQnLXUM">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964028&amp;usg=AOvVaw3MgePRoYclNEYFV7dqByJ-">&nbsp;CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964157&amp;usg=AOvVaw1iK_Sa81McHEeIBw8MUT-t">Nat Commun 2016 71</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964282&amp;usg=AOvVaw0pX5zktrU1PbSE5rafB-j7">&nbsp;2016;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964385&amp;usg=AOvVaw0KcfJQEOd1y2UKUcPTxVtC">7</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964519&amp;usg=AOvVaw14MeNgfE9o8NQc4vrBtbk2">:1&ndash;10.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964783&amp;usg=AOvVaw3stKhruw_RTMn1qbfGd5R7">45. Braig F, Brandt A, Goebeler M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508964897&amp;usg=AOvVaw1pZQOU-QFX3Cw-6IXIUb9S">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508965254&amp;usg=AOvVaw2GjjhnRX0tK2NCXe1X5OJP">&nbsp;Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508965373&amp;usg=AOvVaw2GiAXKHBnoUlBgbjmcn9QR">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508965494&amp;usg=AOvVaw0NHedA9ctEOuq8eNnXiphW">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508965625&amp;usg=AOvVaw3Ckzep_d-bK6bbo4tZrYjC">129</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508965750&amp;usg=AOvVaw3MDjEyDYajSKMOYWvcVgGX">:100&ndash;4.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966038&amp;usg=AOvVaw2nyZX3O-UBc4U0BRPBh5U5">46. Ledererova A, Dostalova L, Kozlova V </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966133&amp;usg=AOvVaw39Xv0S-hkSwByhKTsdLWnj">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966381&amp;usg=AOvVaw2SpY9Op79FiAaa10Fbxrdx">&nbsp;Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966493&amp;usg=AOvVaw3oYkQRwuSqhdPFV6ce8xjj">J Immunother Cancer</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966576&amp;usg=AOvVaw3tTjK9OGUZgr4z5hirVTwc">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966654&amp;usg=AOvVaw2CBhVqNgpq8cMzC_DPXybK">9</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966741&amp;usg=AOvVaw0WLdrjrLP37gZ-Lce9RBvb">:e002352.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508966952&amp;usg=AOvVaw3KJuSEiEpJh3cYnGim0Wvj">47. He C, Mansilla-Soto J, Khanra N </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967069&amp;usg=AOvVaw04La8LYE0hJj0yB8rwSCPr">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967300&amp;usg=AOvVaw0be5BaHrJVe7jp5jTf04T0">&nbsp;CD19 CAR antigen engagement mechanisms and affinity tuning. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967404&amp;usg=AOvVaw3c1hbPdGV1x9UzIos6MY_G">Sci Immunol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967532&amp;usg=AOvVaw3Bp4POkMmiAngZfpynEDpn">&nbsp;2023;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967611&amp;usg=AOvVaw2nzo_f0EiKTJ6AIXvlQxwW">8</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967709&amp;usg=AOvVaw0OVax5hU416oo5uUSJQzNr">:eadf1426.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967905&amp;usg=AOvVaw1tgUmKE3t3RoCdAB4KRcJN">48. Klesmith JR, Wu L, Lobb RR </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508967989&amp;usg=AOvVaw3Dx4aeQSvM7zTv0MXbq0gz">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968176&amp;usg=AOvVaw0ZhzPgYN1jhJ-8EBEDPpN0">&nbsp;Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968295&amp;usg=AOvVaw2rZO8kgX9yxj8HduT0C0Rp">Biochemistry</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968388&amp;usg=AOvVaw1JIkXUWqRThdaPZ-wqDfaa">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968472&amp;usg=AOvVaw0_N635MiZV2HhQnR1wW57f">58</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968611&amp;usg=AOvVaw1JAkpvUyQ8zZmamcpW9W71">:4869&ndash;81.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968822&amp;usg=AOvVaw1Ucaq5xMBgTgvjLEdg0ed1">49. Nicholson IC, Lenton KA, Little DJ </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508968928&amp;usg=AOvVaw2nIW9Ua586erM-6JKkxePc">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969245&amp;usg=AOvVaw2SrUsWD35mpIyAUCk4EiwM">&nbsp;Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969368&amp;usg=AOvVaw1FFdYpiBtuHZBfQIjWiqvH">Mol Immunol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969469&amp;usg=AOvVaw2Pxjc9De_tz83NCsEClyQR">&nbsp;1997;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969575&amp;usg=AOvVaw2NJgGbw2WdLTk2leNKjWNZ">34</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969696&amp;usg=AOvVaw30DIdq-OjD_U5bnOyMWEys">:1157&ndash;65.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508969985&amp;usg=AOvVaw3Wt0Z_Z74pRKmy-SDjrHBR">50. ZOLA H, MACARDLE PJ, BRADFORD T </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970086&amp;usg=AOvVaw1nOtPepuKqz57RI5Peeigp">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970299&amp;usg=AOvVaw1YTGWJs3LQ4Sky4Fxe_zXE">&nbsp;Preparation and characterization of a chimeric CD19 monoclonal antibody. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970403&amp;usg=AOvVaw0Dqnyk71SKjv3GSsTfYYrf">Immunol Cell Biol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970496&amp;usg=AOvVaw3mJ660Oj_PdjoNWYN5Nd6t">&nbsp;1991;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970591&amp;usg=AOvVaw0Y4g6fLJ95lkvxEbtTLC9x">69 ( Pt 6)</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970678&amp;usg=AOvVaw2u67WAbQZegovCh945YmQV">:411&ndash;22.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508970905&amp;usg=AOvVaw3tbBaDhI5Ut8OXagQBh-Fo">51. Binder JL, Berendzen J, Stevens AO </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971029&amp;usg=AOvVaw2OjCU1WZF60yG4yHQr443b">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971316&amp;usg=AOvVaw19WZz332gxqk4rFfSuRe8v">&nbsp;AlphaFold Illuminates Half of the Dark Human Proteins. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971492&amp;usg=AOvVaw0OTZASGd9LJfJhP4uebnBo">Curr Opin Struct Biol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971623&amp;usg=AOvVaw2Lx3KMRmfjQ5a_zQeLvzAa">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971744&amp;usg=AOvVaw0y5zv1m_tu3rt-cibn2cYX">74</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508971871&amp;usg=AOvVaw0kMKbxIk8ICIzJdX-PxSMz">:102372.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508972141&amp;usg=AOvVaw34fbI8NzpOTX3azsR1iwGE">52. Abramson J, Adler J, Dunger J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508972267&amp;usg=AOvVaw3_GGZ1FdOwTXjC9XYFHAEA">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508972583&amp;usg=AOvVaw1W4tSaiTcfO0J0sCNR8vhG">&nbsp;Accurate structure prediction of biomolecular interactions with AlphaFold 3. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508972719&amp;usg=AOvVaw3IGf467icjqnXSE46geYYR">Nature</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508972894&amp;usg=AOvVaw1ztZWFyIiJEK933VznTRTN">&nbsp;2024;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508973021&amp;usg=AOvVaw1yqOb670L5y5bdD89k2ahc">630</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508973129&amp;usg=AOvVaw3ccIGOr0p_klzUGxtwVQb_">:493&ndash;500.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508973640&amp;usg=AOvVaw0dcaPewk7f5kBJomL0tr3w">53. Kantroo P, Wagner GP, Machta BB. Pseudo-perplexity in One Fell Swoop for Protein Fitness Estimation. 2024, DOI: 10.48550/arXiv.2407.07265.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508973895&amp;usg=AOvVaw1gMP2IOxoHK_wOHY6aJr7q">54. Noble J, Locke FL, Savid-Frontera C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974043&amp;usg=AOvVaw1S2HKsxBg2aMeqoCUYyBU7">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974350&amp;usg=AOvVaw0SeQIqNlNkoy6G8KIB9CwG">&nbsp;CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974488&amp;usg=AOvVaw17WRYs_LJO0Ovt3WxBXh1P">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974621&amp;usg=AOvVaw2LC6YMN12Mj37BisvZY6i7">&nbsp;2023;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974745&amp;usg=AOvVaw15PchRIxk53Uu0ADS3yewh">142</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508974889&amp;usg=AOvVaw0Jvv0kNY_bZj8TCKqVaYrH">:3506.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508975207&amp;usg=AOvVaw25S7mQwUfxATpmqVilp27A">55. Topp MS, G&ouml;kbuget N, Zugmaier G </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508975342&amp;usg=AOvVaw0cQTmzB1bz7CAk76KAYmda">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508975933&amp;usg=AOvVaw2dLvojzK5Pu5k_I4DzjbWm">&nbsp;Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976091&amp;usg=AOvVaw3uZLCYwUobSS7jkGyX5zcm">J Clin Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976219&amp;usg=AOvVaw3NzYrr4u6W-ijAGIa1isWx">&nbsp;2014;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976327&amp;usg=AOvVaw02As5MXrg95ryVjaPuaCF6">32</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976476&amp;usg=AOvVaw3ZeOCFeysuaK5Z12xmGL1f">:4134&ndash;40.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976773&amp;usg=AOvVaw3mZDCMPE5iiHr01k_h8zfc">56. Vitolo U, Trn&#283;n&yacute; M, Belada D </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508976907&amp;usg=AOvVaw1HMtebpnL4XrlRkhu1yxxn">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508977381&amp;usg=AOvVaw26SnZdDrLHD7bcsyK-yOWr">&nbsp;Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508977601&amp;usg=AOvVaw1lwAkmXns5_FmTYFB0qk2l">J Clin Oncol Off J Am Soc Clin Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508977743&amp;usg=AOvVaw2-oqQYAZS7_y2azzDmECSy">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508977895&amp;usg=AOvVaw0MFH6fHCBTTcIaTxHySdNc">35</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508977992&amp;usg=AOvVaw2KB15NB50oGm6LwbENk9mV">:3529&ndash;37.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978219&amp;usg=AOvVaw1VKRf2lM76-WxTzTfGAKed">57. McCord R, Bolen CR, Koeppen H </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978307&amp;usg=AOvVaw31IEV94c3yXnOlpGf9jItg">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978476&amp;usg=AOvVaw3mNLeJqDJXG2CL52oqk9En">&nbsp;PD-L1 and tumor-associated macrophages in de novo DLBCL. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978567&amp;usg=AOvVaw1ou8g5P_L9j02IkZoZVmq0">Blood Adv</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978650&amp;usg=AOvVaw3XlyvUVQmIRYbJvgp0HsJ-">&nbsp;2019;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978727&amp;usg=AOvVaw0baYN43iB5Krxh_1f7wgNH">3</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508978822&amp;usg=AOvVaw12cvXPtLRZC0zBZ5M4lIve">:531&ndash;40.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979022&amp;usg=AOvVaw0FVm_ivnRATH1NWGQFzNOY">58. Lonsdale J, Thomas J, Salvatore M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979107&amp;usg=AOvVaw22Iyep0ZEsHmy7Oiqwa5Xu">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979274&amp;usg=AOvVaw32GpqckqfkVPCtIM2UUJUs">&nbsp;The Genotype-Tissue Expression (GTEx) project. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979394&amp;usg=AOvVaw0dUqs-ftORewcgO_4906MF">Nat Genet</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979510&amp;usg=AOvVaw2G2W66eTeFnSBsdfwrJ20o">&nbsp;2013;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979616&amp;usg=AOvVaw3QIh9p67s7viPZvjbkPL8y">45</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508979735&amp;usg=AOvVaw3SnMbKvqnxO_D2JAWnlXiC">:580&ndash;5.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980005&amp;usg=AOvVaw20Y451nYZCCSNT2Volrh3m">59. Toft N, Birgens H, Abrahamsson J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980140&amp;usg=AOvVaw058NkvNp8xRmpGIO4wQpFB">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980537&amp;usg=AOvVaw3VRKM0YTFsc3z7C-QPxbMK">&nbsp;Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980680&amp;usg=AOvVaw0CZiXj3zBppBM87b8f-dFP">Leukemia</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980820&amp;usg=AOvVaw1K87O6gmGvQW_yuYvBDt7c">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508980944&amp;usg=AOvVaw1XQqCAsGzSftkQ4eD44vYj">32</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508981085&amp;usg=AOvVaw1D5VtEYgIb6BPz-wqs5r_S">:606&ndash;15.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508981373&amp;usg=AOvVaw2HvoqMqCMRy8L_N-QfJGvG">60. Chen S, Zhou Y, Chen Y </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508981514&amp;usg=AOvVaw2orXnxk7o9a7YeKEHqCa40">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508981757&amp;usg=AOvVaw13rfW9ccFdOnDaFX-yPNZ1">&nbsp;fastp: an ultra-fast all-in-one FASTQ preprocessor. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508981909&amp;usg=AOvVaw2vIOKqG8aLOdtXrW39QmA1">Bioinforma Oxf Engl</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982035&amp;usg=AOvVaw3VcV9-cLJFQWqJlDeG0G3K">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982164&amp;usg=AOvVaw2OO0vf1OUIO8n6vxOUminw">34</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982306&amp;usg=AOvVaw0BF7MsCl2dObjfMspZJKal">:i884&ndash;90.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982619&amp;usg=AOvVaw2rK2_oy3A5B-LJJmPeEOlO">61. Dobin A, Davis CA, Schlesinger F </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982757&amp;usg=AOvVaw0mdlqQNsAOGNA9V2myS88I">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508982982&amp;usg=AOvVaw2LnAbK0axePw_Civ--XcN-">&nbsp;STAR: ultrafast universal RNA-seq aligner. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983150&amp;usg=AOvVaw2jTw5KAxQNaJzUUzPGVuLX">Bioinforma Oxf Engl</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983285&amp;usg=AOvVaw0JYLFQ9JD0BZ9BRB0U6C-W">&nbsp;2013;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983412&amp;usg=AOvVaw3NVfLP-1GstSnO4M5_hECD">29</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983556&amp;usg=AOvVaw1i65aaR2WHyWk-QFm4H41U">:15&ndash;21.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983861&amp;usg=AOvVaw0A40Mhh3OH3y6nwZVoLsg3">62. Leinonen R, Sugawara H, Shumway M </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508983988&amp;usg=AOvVaw3eGo2fKgpK0799ARCESDFz">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508984159&amp;usg=AOvVaw1tFvjrQ6Z7B9InV6X_-o_c">&nbsp;The Sequence Read Archive. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508984315&amp;usg=AOvVaw26rVwF9RZKhdh3PwOVii0x">Nucleic Acids Res</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508984409&amp;usg=AOvVaw3AIhZKrI4sfWLIesEw8O5c">&nbsp;2011;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508984521&amp;usg=AOvVaw2eqJdKVqnTB_1r0IKkRqCX">39</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508984661&amp;usg=AOvVaw1bbQacsanhR0mH59td9aFg">:D19&ndash;21.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508985158&amp;usg=AOvVaw2BW-Xfhdh7J_1V0kYF-Ggp">63. Charles R. snapcount: R/Bioconductor Package for interfacing with Snaptron for rapid querying of expression counts. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508985343&amp;usg=AOvVaw3hw7Yg57qs0_JoaSiHvf52">R Package Version 1120</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508985498&amp;usg=AOvVaw0GTZg-KF1st7d1XVTp6tU6">&nbsp;2023.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508985827&amp;usg=AOvVaw0-YAWDfIR6ksHGpzm2TtIH">64. Garrido-Mart&iacute;n D, Palumbo E, Guig&oacute; R </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508985965&amp;usg=AOvVaw3SHoHOfodRt7QJ4J5eyIIv">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508986235&amp;usg=AOvVaw2nyo-jUyzCSe9DA-1PTgFK">&nbsp;ggsashimi: Sashimi plot revised for browser- and annotation-independent splicing visualization. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508986352&amp;usg=AOvVaw0syX9dhKlL_jaL_1uBpKLF">PLOS Comput Biol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508986468&amp;usg=AOvVaw1sgiL2UuT3gZIyP_M--SIP">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508986572&amp;usg=AOvVaw31h_vNHW2MrGoaROKfx7T6">14</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508986715&amp;usg=AOvVaw3tdxz5yB5jJU59TiyWnmmD">:e1006360.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987037&amp;usg=AOvVaw24GWpACw4_XEOjrv_axehH">65. Bodenhofer U, Bonatesta E, Horej&scaron;-Kainrath C </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987169&amp;usg=AOvVaw1vvAF4-FYtxcINknkiA30g">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987400&amp;usg=AOvVaw1Bzc3I9vCLsrWEjYfRcXB7">&nbsp;msa: an R package for multiple sequence alignment. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987559&amp;usg=AOvVaw1ThW8mpzL--HvRNXGXkcBL">Bioinformatics</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987691&amp;usg=AOvVaw2lMsRR6xklbZ5unj1poMbw">&nbsp;2015;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987815&amp;usg=AOvVaw3sPAcOWYV6JQHhp5Rm-2VF">31</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508987948&amp;usg=AOvVaw1vPn0Wa8LfuZNsnRIeDKXc">:3997&ndash;9.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508988176&amp;usg=AOvVaw2vTDOlZp3SEqHCrE6_tkxW">66. Hallgren J, Tsirigos KD, Pedersen MD </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508988269&amp;usg=AOvVaw0hwp923ccenvg5Si1oZ2rG">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508988527&amp;usg=AOvVaw19r7TpiKUCyFijUFlQZixa">&nbsp;DeepTMHMM predicts alpha and beta transmembrane proteins using deep neural networks. 2022:2022.04.08.487609.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508988834&amp;usg=AOvVaw2NbhMbqVROfYAqfmUgYcbV">67. Schr&ouml;dinger L, DeLano W. PyMOL. 2020.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508989112&amp;usg=AOvVaw0ZY6R3d9cd_lFji31nDvYo">68. Hsu C, Verkuil R, Liu J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508989212&amp;usg=AOvVaw16g7kknA4JMk13sgA0dnmg">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508989498&amp;usg=AOvVaw2Ko2SO_7hsPlzPP97-xNUe">&nbsp;Learning inverse folding from millions of predicted structures. 2022:2022.04.10.487779.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508989752&amp;usg=AOvVaw328ufcSlLlBUFLW-ykdFGf">69. Song Y, Botvinnik OB, Lovci MT </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508989859&amp;usg=AOvVaw1QCdrkko9l1BYBgi7qcJ4G">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508990245&amp;usg=AOvVaw0rZroQIaYJ7seqxK4ULSzz">&nbsp;Single-Cell Alternative Splicing Analysis with Expedition Reveals Splicing Dynamics during Neuron Differentiation. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508990388&amp;usg=AOvVaw2qyUsgiRPqA36PhO2oCgKh">Mol Cell</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508990570&amp;usg=AOvVaw36Ztu4mo4qdoDN1wv0Pelm">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508990721&amp;usg=AOvVaw1DPbEdZFm705qtjOgK_gJb">67</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508990875&amp;usg=AOvVaw1ymSiPW2-BC0XZpHc5iix2">:148-161.e5.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991134&amp;usg=AOvVaw2rO9TwUnYDTvB1EQQ6gAVY">70. Litzow MR, Sun Z, Mattison RJ </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991319&amp;usg=AOvVaw0N6LiOByBAWHLlzelFd1R6">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991548&amp;usg=AOvVaw0Kgu_CjKXYgqeQyr91NTA1">&nbsp;Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991650&amp;usg=AOvVaw2vG7gqV9i9bD7UebEEnDJg">N Engl J Med</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991733&amp;usg=AOvVaw3-ey_gq2tevJIlCpmrQrxp">&nbsp;2024;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991813&amp;usg=AOvVaw3AvKroDjU6uwCqhm5iUxsr">391</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508991921&amp;usg=AOvVaw21lke_n5tBAuz69cNwqUe6">:320&ndash;33.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992138&amp;usg=AOvVaw2P82AZ-pzKOsKP2w8g5fQN">71. Plaks V, Rossi JM, Chou J </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992266&amp;usg=AOvVaw0g53kU_CaxPeyGJ6HVDHvw">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992519&amp;usg=AOvVaw3btmTSICsqU-wGkGIgv9uY">&nbsp;CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992600&amp;usg=AOvVaw0kBvwOpKSO1n3AiXZSLu5O">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992682&amp;usg=AOvVaw0TjbbVSX8Nc45WVkDr11Wj">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992765&amp;usg=AOvVaw0VkMKHIQ0oftq-ZCu6sp-i">138</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508992872&amp;usg=AOvVaw1WvD30RV2KaWROFjGquX6i">:1081&ndash;5.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993116&amp;usg=AOvVaw2hkYMpBAB0dI4Y7Kr8UohY">72. Fousek K, Watanabe J, George A </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993213&amp;usg=AOvVaw2Ly5MgEPiG8BLRLCvYq_Bm">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993476&amp;usg=AOvVaw3e35Hy6uXQ-vHPaJeLhZFA">&nbsp;Targeting Primary Pre-B Cell Acute Lymphoblastic Leukemia and CD19-Negative Relapses Using Trivalent CAR T Cells. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993613&amp;usg=AOvVaw0gr8sMqW5kt3ZaKAIOfKAs">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993701&amp;usg=AOvVaw1jk0DghwjqzrXrrHMs2S1X">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993780&amp;usg=AOvVaw2EN0OIflri3wpyZ9Bgl7I6">130</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508993862&amp;usg=AOvVaw0GlG8Jdt7IsccXyC7DkjC_">:4614.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994062&amp;usg=AOvVaw19i4b57oOlFamyBeygEOcx">73. Martyniszyn A, Krahl A-C, Andr&eacute; MC </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994147&amp;usg=AOvVaw0xA2E4nYSHgMpwdu6WsA9C">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994342&amp;usg=AOvVaw0QIDeXJN4e8HDa1q9AiED7">&nbsp;CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994438&amp;usg=AOvVaw2Cby9c_ZVO4iRKP8MPMXi5">Hum Gene Ther</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994520&amp;usg=AOvVaw19WVClLZ77B5gw3lAcGlMl">&nbsp;2017;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994618&amp;usg=AOvVaw2T5a-O_v-_8FvZotErMOQ4">28</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994728&amp;usg=AOvVaw2pskfLFrlXzuYDJJUBmUgh">:1147&ndash;57.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508994910&amp;usg=AOvVaw2NBqn2F8nNo7w7ZKvYxPVY">74. Dai H, Wu Z, Jia H </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995033&amp;usg=AOvVaw0KCHRy-kGfR__8SK9tuYle">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995334&amp;usg=AOvVaw2qSQrXkWOejXve9t_dd_Np">&nbsp;Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995554&amp;usg=AOvVaw2ENjaTYAEGgUE5AdSBVbZx">J Hematol OncolJ Hematol Oncol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995640&amp;usg=AOvVaw1Ju3YTQbvS6HwTgUdbIETb">&nbsp;2020;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995721&amp;usg=AOvVaw2SBb6_xsMHY_zp2oZV6SI7">13</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508995827&amp;usg=AOvVaw3qOfIUgE2d_D__ZnsJjpu9">:1&ndash;10.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996043&amp;usg=AOvVaw3U8WbD5lYQVnnXXnFKWJIE">75. Liu S, Deng B, Yin Z </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996128&amp;usg=AOvVaw2L62tyUW74N0x0g-Du2dl0">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996404&amp;usg=AOvVaw2FFnmB7UWEph1plhdGt08u">&nbsp;Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996500&amp;usg=AOvVaw1P1vLvtA3OAerYEShBxz9L">Am J Hematol</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996588&amp;usg=AOvVaw2mhqPLcZ3CW9d6z4tqmaL8">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996670&amp;usg=AOvVaw23txCtVA-p27CWkD1JXEDZ">96</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508996754&amp;usg=AOvVaw1mULAF0hqRXYtX4koprPRU">:671&ndash;9.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997041&amp;usg=AOvVaw2WofH7aPFW68JbwPI96_pg">76. Shah NN, Sokol L. Targeting CD22 for the Treatment of B-Cell Malignancies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997156&amp;usg=AOvVaw2K88u_71ZlLkJ8lhWzwxOC">ImmunoTargets Ther</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997240&amp;usg=AOvVaw0cOH_a0aXurt-_r4ceTDPl">&nbsp;2021;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997338&amp;usg=AOvVaw3Ja16MfOZiqWKs5nHl6ZL3">10</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997447&amp;usg=AOvVaw2I_pXucJRBbK15ArqbHsw-">:225&ndash;36.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997643&amp;usg=AOvVaw0US-3SSOl4XB-ro8o7kAtX">77. Ruella M, Barrett DM, Kenderian SS </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997726&amp;usg=AOvVaw3ZT-PhDo1GxJUHu8e5vvY1">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508997958&amp;usg=AOvVaw0HkX8hfA50W1NSp2UKgc0h">&nbsp;Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998059&amp;usg=AOvVaw3rqaizmA0aCjInqPvgcq5I">J Clin Invest </a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998139&amp;usg=AOvVaw1sBSs_VdGz3Q_SC5u2QX9w">126</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998234&amp;usg=AOvVaw0mrUvCmvp1JdElKKG8II07">:3814&ndash;26.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998424&amp;usg=AOvVaw24xh1zSS9PPb36Bpi4RcAi">78. Chu F, Weng J, Kuang S-Q </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998516&amp;usg=AOvVaw2IC6gENs5Zf0PKNYfks-xg">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998762&amp;usg=AOvVaw3xMNwOLpOWvLwmOOYfQOgT">&nbsp;Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cell Malignancies. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998844&amp;usg=AOvVaw1sFHsPlJVyf-23pNCwSadm">Blood</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998924&amp;usg=AOvVaw3d8i152uE5IpNlgqvcQm3R">&nbsp;2018;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508998998&amp;usg=AOvVaw3KfSzLeUULazBQwniSOt14">132</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999087&amp;usg=AOvVaw3RuvUALAOdhCtp9RMlRzm8">:1662&ndash;1662.</a></span></p><p class="c9"><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999260&amp;usg=AOvVaw3r5P7zSa0c2bTUAAvnqbIP">79. Chen M, Fu M, Wang A </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999347&amp;usg=AOvVaw0fDgEfgvrgfDjSKsItcqtO">et al.</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999613&amp;usg=AOvVaw3x_CyvNz5IobufJ1iIoaHK">&nbsp;Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy. </a></span><span class="c4"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999712&amp;usg=AOvVaw1mNnbrX2BDZCD0S_etjdiM">Leuk Lymphoma</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999794&amp;usg=AOvVaw2rFEZaJRi2Dt3CTut-js56">&nbsp;2022;</a></span><span class="c15 c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999868&amp;usg=AOvVaw1_NnFgHXOitFDEKMdBU9R_">63</a></span><span class="c6"><a class="c2" href="https://www.google.com/url?q=https://www.zotero.org/google-docs/?LTs41P&amp;sa=D&amp;source=editors&amp;ust=1761295508999961&amp;usg=AOvVaw1Dmre0QieBXtuWWyWQgwSa">:426&ndash;34.</a></span></p><p class="c35 c62"><span class="c1"></span></p><div class="c0"><p class="c31"><a href="#cmnt_ref1" id="cmnt1">[a]</a><span class="c1">Smider lige et par links her som vi m&aring;ske kan bruge</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref2" id="cmnt2">[b]</a><span class="c1">Overblik over godkendte anti CD19 CAR T drugs: https://chi.scholasticahq.com/article/124277-overview-of-approved-car-t-products-and-utility-in-clinical-practice?attachment_id=247987</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref3" id="cmnt3">[c]</a><span class="c1">Sygdomme Breyanzi er godkendt til at behandle: https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref4" id="cmnt4">[d]</a><span class="c1">Tecartus: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref5" id="cmnt5">[e]</a><span class="c1">Kymriah: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref6" id="cmnt6">[f]</a><span class="c1">Yescarta: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref7" id="cmnt7">[g]</a><span class="c1">Lars tager sig af dette</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref8" id="cmnt8">[h]</a><span class="c1">Can probably be phrased better</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref9" id="cmnt9">[i]</a><span class="c1">Other columns to add?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref10" id="cmnt10">[j]</a><span class="c1">Comprises 4 studies of samples sizes&nbsp;49, 13, 12, 12</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref11" id="cmnt11">[k]</a><span class="c1">Jeg ville tilf&oslash;je en masse data om b&aring;de ALL og DLBCL kohorterne, antal, alder, behandling, ect.</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref12" id="cmnt12">[l]</a><span class="c1">@Signe</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref13" id="cmnt13">[m]</a><span class="c1">Vil I gerne have det i tabelform?</span></p><p class="c31 c35"><span class="c1"></span></p><p class="c31"><span class="c1">Som n&aelig;vnt mangler jeg kliniske data (ud over alder, k&oslash;n og immunf&aelig;notype) fra omkring 1/3 da disse blev diagnosticeret i ALLTogether pilotperioden og derfor ikke er i nogen af database udtr&aelig;kkene.&nbsp;</span></p><p class="c31"><span class="c1">Hvis du gerne vil have det klar inden forsvaret p&aring; fredag, kan jeg lave en tabel for de patienter, jeg har data p&aring;, og ellers kan vi ogs&aring; vente til jeg har skaffet det sidste data.&nbsp;&nbsp;</span></p><p class="c31"><span class="c1">Det drejer sig om tumorbyrde (marv blastprocent, blod WBC, CNS involvering), behandlingsrespons (end of induction MRD) og outcome (relaps/d&oslash;d/sekund&aelig;r malignitet/HSCT). Vi kan selvf&oslash;lgelig ogs&aring; n&oslash;jes med at inkludere info om alder og k&oslash;n, idet vi jo alligevel ikke sammenholder med outcome i denne kohorte... men alts&aring;, blastprocenten i marv vil v&aelig;re rar at have!</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref14" id="cmnt14">[n]</a><span class="c1">Det er ikke brandende vigtigt inden mit forsvar</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref15" id="cmnt15">[o]</a><span class="c1">inden submission skal Karin og Kjeld lige se den og skrive lidt til denne del ogs&aring;. Vi skal ogs&aring; lige have et VEK nr p&aring; - skal jeg involvere dem nu eller vil I vente?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref16" id="cmnt16">[p]</a><span class="c1">Add&nbsp; 36867678 (structure)</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref17" id="cmnt17">[q]</a><span class="c1">/home/projects/dp_immunoth/people/s153398/relapseR/figs/sashimi.svg</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref18" id="cmnt18">[r]</a><span class="c1">Og vi har rettigheder? (Du har sikkert styr p&aring; det, men vil s&aring; n&oslash;dig forstyrre folk p&aring; barsel :)</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref19" id="cmnt19">[s]</a><span class="c1">Den er skrivebeskyttet, men I kan kopiere den</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref20" id="cmnt20">[t]</a><span class="c1">@giorgia.moranzoni@gmail.com Can you please add time to response below the patient names in the rows?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref21" id="cmnt21">[u]</a><span class="c1">Could you also please add A and B to the pre and post treatment panels?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref22" id="cmnt22">[v]</a><span class="c1">Hvor stor en andel er &lt;100%?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref23" id="cmnt23">[w]</a><span class="c1">86.8%</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref24" id="cmnt24">[x]</a><span class="c1">i DLBCL</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref25" id="cmnt25">[y]</a><span class="c1">@soren.helweg@gmail.com Vil du udregne for resten ogs&aring;?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref26" id="cmnt26">[z]</a><span class="c1">B-ALL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.8400000</span></p><p class="c31"><span class="c1">Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.8550186&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p><p class="c31"><span class="c1">DLBCL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.8675889&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p><p class="c31"><span class="c1">Spleen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.8393574</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref27" id="cmnt27">[aa]</a><span class="c1">`sum(psi &lt; 1) / n()`</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref28" id="cmnt28">[ab]</a><span class="c1">@giorgia.moranzoni@gmail.com I think we need an adjustment to this figure as well. Probably easier to do with S&oslash;rens R script than with Illustrator. I think the y axes should be Percent of samples rather than # of samples. Can you fix?</span></p><p class="c31"><span class="c1">_Assegnato a giorgia.moranzoni@gmail.com_</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref29" id="cmnt29">[ac]</a><span class="c1">File: /home/projects/dp_immunoth/people/s153398/relapseR/figs/PSI_full.png</span></p><p class="c31"><span class="c1">Code: /home/projects/dp_immunoth/people/s153398/relapseR/R/03_Fig3_PSI_plot.Rmd</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref30" id="cmnt30">[ad]</a><span class="c1">Det er rigtig interessant ogs&aring;! M&aring;ske ogs&aring; n&aelig;vne frekvensen af intron2 retention i de andre kohorter?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref31" id="cmnt31">[ae]</a><span class="c1">Adding to the complexity, although only shown in CLL, hypermethylation silencing of CD19 may play a role and require separate testing [40]. Furthermore, elevated IL-6 levels during CAR-T therapy have been linked to increased lineage switching, which would also require a separate measure for detection [39].</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref32" id="cmnt32">[af]</a><span class="c1">[40] Ledererova, 2021</span></p><p class="c31"><span class="c1">[39] Jacoby, 2016</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref33" id="cmnt33">[ag]</a><span class="c1">Similarly, bispecific antibodies and de-methylation agents have shown promising effects in B-ALL/DLBCL and CLL, respectively [21,34,53].</span></p><p class="c31"><span class="c1">[21] Frontzek</span></p><p class="c31"><span class="c1">[34] Topp</span></p><p class="c31"><span class="c1">[53] Qi Blinatimumab</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref34" id="cmnt34">[ah]</a><span class="c1">Another study found that a de-methylating agent could prevent target loss in some patients where the promoter region of CD19 was hypermethylated.</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref35" id="cmnt35">[ai]</a><span class="c1">ER retention of &#120491;exon2 splice variant [59]</span></p><p class="c31"><span class="c1">[59] Bagashev, 2018</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref36" id="cmnt36">[aj]</a><span class="c1">My translation of &quot;makes a case that AbAg structures where the Ab is in the wrong orientation, or simply does not match with the antigen, end up with low confidence scores&quot;. but maybe I am misrepresenting the reference?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref37" id="cmnt37">[ak]</a><span class="c1">Just want to highlight here that pseudo-perplexity mainly makes sense as a relative measure (% drop in variant vs wild-type). Maybe add scores on top of the bars here?</span></p><p class="c31 c35"><span class="c1"></span></p><p class="c31"><span class="c1">For pLDDT, the alphafold FAQ elaborates that the dynamic range we&#39;re interested in is mainly 100-70, and anything below 50 should &quot;not be interpreted&quot; as it is &quot;a strong predictor of disorder&quot;.&nbsp; Since we&#39;re calculating mean pLDDT values here, a difference of e.g. 80 vs 70 is even more pronounced. All this to say, I think it&#39;s fair to show the graph from 50-100 here</span></p><p class="c31 c35"><span class="c1"></span></p><p class="c31"><span class="c1">https://alphafold.ebi.ac.uk/faq</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref38" id="cmnt38">[al]</a><span class="c1">Thanks! Just yesterday, we were discussing how significant these drops actually are. Great to hear they are decently significant!</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref39" id="cmnt39">[am]</a><span class="c1">Since these are mean values (over residues, I suppose?) would it make sense to show the variance? Would it make sense to calculate a p value for the drop?</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref40" id="cmnt40">[an]</a><span class="c1">Showing a p-value/variance with the 2 structures here doesn&#39;t make so much sense to me, given that the residue pLDDTs (or positional perplexities) are not independent of each other. However, it would make sense to e.g. re-run the AlphaFold structures 20x and calculate variance in the pLDDT mean -&gt; p-value significance testing between structure 1 and 2. Note that you&#39;re pretty much guaranteed significance with enough re-runs though, so a discussion of the magnitude of the change is probably more informative</span></p></div><div class="c0"><p class="c31"><a href="#cmnt_ref41" id="cmnt41">[ao]</a><span class="c1">File: /home/projects/dp_immunoth/people/s153398/relapseR/figs/AF_barchart.png</span></p><p class="c31"><span class="c1">Code: /home/projects/dp_immunoth/people/s153398/relapseR/R/FigS1_AF_confidence_barchart.R</span></p></div></body></html>